Comprehensive Forced Degradation Study Revealing Diverse Chemical and Physical Degradation Pathways of AAV8

Comprehensive Forced Degradation Study Revealing Diverse Chemical and Physical Degradation Pathways of AAV8 | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Comprehensive Forced Degradation Study Revealing Diverse Chemical and Physical Degradation Pathways of AAV8 Li Zhi, Kuan-Yu Lai, Song Nie, Yu-Chieh (Ariel) Chen, Timothy Tiambeng, and 12 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-7596388/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 12 Feb, 2026 Read the published version in Gene Therapy → Version 1 posted 9 You are reading this latest preprint version Abstract While recombinant adeno-associated virus (AAV) holds significant promise for effective and durable gene delivery for gene therapy, a thorough understanding of the critical quality attributes (CQAs) along with the degradation pathways of AAV under the various stresses that may occur during manufacturing, storage, and handling remains limited. To address this gap, we performed a comprehensive forced degradation study to elucidate the degradation pathways of AAV8 under a series of stress conditions such as oxidation, extreme pH, high temperature, freeze thaw, and agitation. Our results show that, under these stress conditions, distinct post-translational modifications (PTM), including methionine oxidation, asparagine deamidation, and aspartic acid isomerization, along with multiple physical degradation pathways, including capsid aggregation, viral protein fragmentation, and genome DNA leakage, could occur. Alterations in AAV8 biological activity were frequently attributed to the combination effect from chemical and physical degradation mechanisms. The results from this study provide a valuable insight into establishment of stability-indicating methods and identification of CQAs for AAV. It will also support the development of robust manufacturing process as well as stable and efficacious AAV gene therapy drug products. Biological sciences/Biotechnology/Gene therapy Biological sciences/Biological techniques/Biophysical methods Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Introduction Recombinant adeno-associated virus (AAV) has attracted considerable attention for i n vivo gene delivery owing to its distinctive attributes for establishing durable gene expression in various target tissues and demonstrated safety and efficacy as a leading gene delivery tool. In recent years, remarkable progress has been made in the clinical application of AAV gene therapy. To date, eight AAV-based gene therapy products have received regulatory approval, and over 300 clinical trials are currently underway ( 1 , 2 ). Gene therapy represents a groundbreaking approach to potentially curing previously untreatable genetic diseases. It also addresses unmet medical needs in chronic and prevalent human diseases by offering more tolerable treatment options. Clinical studies and the regulatory approval process for AAV gene therapies often utilize a fast-track or accelerated approach, in contrast to the traditional development lifecycle for biological drugs. This reduced timeline, combined with often limited AAV materials during development, can pose significant challenges to the Chemistry, Manufacturing, and Controls development of AAV products. Comprehensive studies to support the development of optimal drug substance and drug product manufacturing process, stable formulations, and robust analytics often fail to be carried out for AAV products, especially prior to First-in-human studies. To mitigate the risks associated with an accelerated development approach, acquiring a thorough understanding of the critical quality attributes (CQAs) along with the degradation pathways of AAV under the various stresses that may occur during manufacturing, transport, storage, and clinical handling is highly desirable. This is particularly important for AAV, given the complexity of its molecular structure. AAV is a non-enveloped virus containing an icosahedral capsid encapsulating a single-stranded DNA genome of 4.7 kb flanked by a 145 bp Inverted Terminal Repeat at each end. The capsid is assembled by 60 viral proteins (VP) with VP1, VP2, and VP3 at a molar ratio of 1:1:10. VP1 is the longest among the three VP proteins, extending 137 amino acids beyond VP2 ( 3 ). This additional segment, known as the VP1 unique (VP1u) region, exhibits phospholipase A2 activity and is implicated in nuclear localization ( 4 – 6 ). VP3 is composed of conserved β-strands linked by surface exposed variable loops which are known to be critical in determining the tropism of distinct AAV serotypes ( 6 ). Furthermore, AAV capsids have unique structural features that are critical to their function. These include channels with pore-like openings at each five-fold axis, which are essential for genome packaging and the externalization of VP1u during endosomal trafficking ( 7 – 9 ). Additionally, the capsids exhibit protrusions surrounding the three-fold axis that play a pivotal role in targeting cell surface ( 10 ). These structural elements have been proposed to play a crucial role in the mechanisms by which AAV interacts with cellular surfaces and delivers transgenes into the nuclei of target tissues or cells. Similar to protein-based therapeutics, instability of AAVs can be mediated by either chemical or physical degradation pathways, or the combination of both ( 11 ). The most commonly observed chemical degradation mechanisms include amino acid modifications such as deamidation, oxidation, and isomerization ( 11 , 12 ). In contrast, physical degradation often arises from conformational, colloidal, and interfacial mechanisms resulting in denaturation, aggregation, surface adsorption, and associated product loss ( 13 ). One unique physical degradation pathway of AAV is vector genome DNA leakage which has been observed under various stress conditions such as freeze-thaw and elevated temperatures ( 14 – 16 ). It is presumably caused by conformational changes of AAV capsids leading to potential widening of the pore structure at the five-fold axis on the AAV capsids where DNA extrusion may occur ( 17 ). AAVs are commonly stored under frozen conditions and may encounter many stress factors during drug substance and drug product manufacturing, transport, storage, and clinical handling ( 11 , 18 , 19 ). These stress factors may include pH extremes, temperature variations, oxidation, multiple freeze thaw cycles, and mechanical stress. In this study, we applied these different types of stress to AAV8 in an optimized formulation. The conditions selected for this study are more extreme than what are typically used during routine stability assessment. The goal of this study is to generate degradation products which help to determine the degradation pathways of AAV8 under each stress condition. The results from these studies will be valuable for determining the CQAs of AAV8, supporting the development of robust formulation and stability indicating assays, as well as contributing to the assessment of manufacturing comparability to ensure consistent manufacturing of safe and effective AAV products for clinical applications. In addition, these results will further help to ensure the success with regulatory submissions, especially as the regulatory framework for gene therapies continues to evolve significantly. Materials and Methods Materials AAV8 encoding a therapeutic transgene was produced using triple transfection approach in HEK293 cells by Virus Production Core at Regeneron Pharmaceuticals, Inc. (Tarrytown, NY, United States). All other excipients and reagents are reagent or compendial grades. Stress Conditions AAV8 material was formulated with a base formulation buffer or dialyzed into the buffer of interest to achieve a target concentration of 2.0E + 13 vg/mL. The base formulation includes a buffering agent to maintain a neutral pH and other excipients to maintain AAV8 stability. Buffer exchange was performed using Slide-A-Lyzer dialysis cassettes with a 10 kDa molecular weight cutoff (Thermo Fisher, Waltham, MA). After formulation or dialysis, the AAV8 was filled into cyclic olefin polymer vials (West Pharmaceutical, Exton, PA). To evaluate the impact of oxidative stress on AAV8, the samples were exposed to hydrogen peroxide (H 2 O 2 ) concentrations of 1 ppm and 1000 ppm, respectively, followed by incubation at 25°C for 1 week. Untreated virus incubated under the same 25°C condition was used as a control. Upon completion of the incubation, the samples were dialyzed into the base formulation using the 10 kDa molecular weight cutoff Slide-A-Lyzer dialysis cassettes to remove residual H 2 O 2 . For the pH stress study, AAV8 was dialyzed into two different buffers at pH 3.0 (Glycine based buffer) and pH 9.0 (Bis-Tris Propane based buffer). Following dialysis, the samples were incubated at 25°C for 1 day and 1 week. To assess the effect of temperature on AAV8 stability, AAV8 was stored at 40°C and 45°C for 1, 2, and 4 weeks. The stability of AAV8 under freeze-thaw stress was assessed by subjecting the samples to 2 or 4 freeze-thaw cycles between − 80°C and room temperature. For the agitation stress study, the samples were vortexed at 1000 rpm for 60 minutes or 120 minutes on a benchtop vortexer. In Vitro Protein Expression Assay The in vitro protein expression assay utilized a proprietary engineered cell line to analyze the expression level of the protein encoded by the transgene encapsidated in AAV8. These cells were seeded and incubated with AAV8, along with a proprietary gene editing reagent. After transduction, the protein of interest was analyzed using an in-house ELISA-based method. The signal versus log dilution was evaluated using non-linear regression analysis with GraphPad Prism 10.1 (Dotmatics, Boston, MA). All critical reagents used in the assay are protected under proprietary rights. Post-translational Modification (PTM) Analysis by liquid chromatography mass spectrometry (LC-MS/MS) The AAV samples under different stress conditions were prepared for PTM analysis by LC-MS/MS based on the previously developed method with minor modifications ( 20 ). Briefly, a total of approximately 7 µg of AAV capsids from each sample was digested with a trypsin/rLys-C mixture (1:1 w/w ratio) at an enzyme-to-substrate ratio of 1:5 (w/w) at 37°C for 2 hours after denaturation, reduction, and alkylation. After digestion, 3 µL of 10% formic acid was added to quench the digestion. The digests were transferred to sample vials, and approximately 2.7 µg of the digests were injected for LC-MS/MS analysis. All the AAV8 samples were analyzed on an Orbitrap Exploris 480 mass spectrometer system coupled with a Vanquish Flex UPLC (Thermo Fisher). The digested peptides were separated on an ACQUITY Premier Peptide CSH C18 column (130 Å, 1.7 µm, 2.1 mm × 150 mm, Waters) at a flow rate of 0.25 mL/min using a 75-minute gradient from 0.1% to 32% mobile phase B, then increasing to 45% buffer mobile phase B in 15 minutes. Mobile phase A and B were 0.1% (v/v) formic acid in water and 0.1% (v/v) formic acid in acetonitrile, respectively. The column temperature was set at 40°C. The mass spectrometer was set up with a 3.5 kV source voltage, a capillary temperature of 320°C, a sheath gas flow of 35, an auxiliary gas flow of 10, and an S-lens RF level of 50. MS1 data was collected in the range of 300 to 2000 m/z with a resolution of 120 K. The top 15 peptides were selected for MS/MS analysis at an HCD normalized collision energy of 30% and a resolution of 15 K. All the raw data were searched with Byonic software Version 5.8.6 (Protein Metrics, Cupertino, CA). Skyline software (MacCoss Lab Software, Seattle, WA) was used for PTM quantification by importing the search data from Byonic. To align the modification locations in the different VP proteins, all the modification sites were mapped to the VP1 sequence unless otherwise noted. Particle Size Distribution by Dynamic Light Scattering (DLS) Particle size distribution was assessed using a Zetasizer Ultra DLS instrument (Malvern, Westborough, MA) with a low-volume quartz cuvette (Malvern). Measurements were taken at a 90° angle, with each sample subjected to five replicate scans, each comprising 10 acquisitions of 10 seconds. Data was collected and analyzed with ZSXplorer software (Malvern). Vector Genome Titer by Droplet Digital Polymerase Chain Reaction (ddPCR) The AAV8 samples were subjected to treatment with DNase I (Thermo Fisher) to eliminate un-encapsulated DNA, followed by digestion of the AAV8 capsids using proteinase K (Thermo Fisher). The digested samples were then diluted with dilution buffer (20 mM Tris, 0.05% (v/v) Pluronic F-68, 0.002 µg/µL sheared salmon sperm DNA, pH 8.0) to achieve a target concentration range of 200 to 8,000 copies/µL, combined with ddPCR master mix (Bio-Rad, Hercules, CA) and transgene specific primer probe set, and partitioned on a AutoDG droplet generator (Bio-Rad). Polymerase Chain Reaction amplification was subsequently performed using a thermocycler (Bio-Rad), and the resulting droplets were analyzed with QxManager Software on a QX-200 droplet reader (Bio-Rad) to quantify the vector genome titer. Capsid Recovery Analysis by Size-Exclusion Chromatography (SEC) Capsid recovery was assessed using SEC on an ACQUITY UPLC H-Class system equipped with PDA and FLR detectors (Waters, Milford, MA) ( 16 ). The analysis employed a Sepax SRT SEC-1000 Column (Sepax, Newark, DE). Analyte separation was carried out using isocratic elution at a flow rate of 0.35 mL/min with a total runtime of 40 minutes. The mobile phase consists of 20 mM sodium phosphate, 300 mM sodium chloride, and 0.02% (w/v) poloxamer 188 at a pH of 7.3. Empower software (Waters) was used for peak integration and identification. Free DNA Analysis by Fluorescence-Based Dye Binding Assay Free DNA analysis was performed using the Qubit™ ssDNA Assay Kit (Thermo Fisher). Stressed AAV8 samples were diluted in AAV8 formulation buffer and mixed with the Qubit™ solution. Standards and test articles were loaded into a black 96-well microplate (Greiner Bio-One, Monroe, NC) and fluorescence was measured at 500 nm excitation and 525 nm emission using a Synergy Neo2 reader (Agilent, Santa Clara, CA). The percentage of free DNA was calculated by comparing to the free DNA level in a positive control AAV8 sample incubated at 75°C for 40 minutes. Determination of Onset Temperature for Genome DNA Release (T) by Differential Scanning Fluorimetry (DSF) T onset of untreated AAV8 sample was determined using DSF on an Uncle system (Unchained Labs, Pleasanton, CA). SYBR® Gold Nucleic Acid Gel Stain (Thermo Fisher) was diluted to the appropriate concentration using AAV8 formulation buffer and then combined with the AAV8 sample. A total of 9 µL of the prepared mixture was loaded into the Unis (Unchained Labs) for melting temperature (T m ) analysis using a thermal ramp from 20°C to 95°C with a heating rate of 0.5°C per minute and a hold time of 60 seconds at each temperature step. SYBR® Gold was excited using a 473 nm laser. T onset value of AAV8 was determined based on the fluorescence intensity area between 500 nm and 650 nm across the temperature range using the Uncle software (Unchained Labs). VP Ratio Analysis by Microfluidic Electrophoresis The VP ratio of AAV8 samples was analyzed using microfluidic electrophoresis on a LabChip® GXII Touch™ HT protein characterization system (Revvity, Waltham, MA) with the HT Protein Express LabChip (Revvity) and Pico Protein Express assay reagent kit (Revvity). Samples were diluted to 1.0E + 13 cp/mL in phosphate-buffered saline (Corning, NY, United States). Then, a total of 10 µL of reducing sample buffer (60 mM phosphate, 1.2% (w/v) lithium dodecyl sulfate, 80 mM dithiothreitol, pH 8.0) was added to 40 µL of the diluted sample. Following a 10-minute denaturation at 75°C, 5 µL of 16 µM dye was added to 5 µL of the sample mixture, incubated at 35°C for 15 minutes, then further diluted with 105 µL dilution solution provided in the kit. The LabChip was prepared according to the manufacturer's instructions. Data processing was performed using Empower software (Waters), and the calculation was conducted by integrating the signal from three major peak species observed in the electropherogram. To determine the VP ratio, the corrected peak area for each VP was divided by the total number of lysine residues in the respective VP, and the resulting values were used to calculate the VP ratio. Results The manufacturing of AAV involves a complex series of processes that can expose the virus to various stress factors such as oxidation, acidic and basic pH conditions, high and low temperatures, freeze-thaw and agitation. To identify potential degradation pathways, AAV8 was subjected to relevant stress conditions as described in Table 1 . Under each stress condition, the impact on the biological activity of AAV8 was first assessed using an in vitro transgene expression assay. Subsequently, potential degradation pathways were examined by measuring changes in several key AAV attributes. Potential chemical degradation, indicated by the formation of various PTM, was studied using an extensive LC-MS-based reduced peptide mapping method. Meanwhile, potential physical degradation pathways such as capsid aggregation, genome DNA release, capsid fragmentation, and associated titer loss were evaluated using various techniques. Specifically, capsid aggregation was probed by measuring the particle size distribution with DLS and the recovery of monomeric AAV using SEC. Genome DNA release was studied through a fluorescence-based DNA dye binding assay. Potential capsid fragmentation was evaluated using a microfluidic electrophoresis method. Finally, changes in vector genome titer were analyzed via ddPCR. Stability Changes of AAV8 Under Oxidative Stress During biopharmaceutical drug product manufacturing process, vaporized hydrogen peroxide is commonly used to decontaminate isolators prior to aseptic filling. As a result, AAV products may be exposed to oxidative stress at about 1 ppm H 2 O 2 from the residual vaporized hydrogen peroxide during manufacturing ( 21 ). In this study, AAV8 at a concentration of 2E + 13 vg/mL were subjected to oxidative stress by incubation with 1 ppm and 1000 ppm H 2 O 2 for one week at room temperature. Following the oxidative exposure, we found that under the highest oxidative stress condition (1000 ppm H 2 O 2 ) assessed, a substantial reduction in AAV8 transgene expression was observed (Fig. 1 A). In contrast, transgene expression remained stable under mild oxidative condition (1 ppm H 2 O 2 ) when compared to control. Oxidation induced by exposure to hydrogen peroxide is known to affect the stability and biological activity of therapeutic proteins ( 22 ) by altering the protein primary structure through chemical modification of amino acid side chains. To characterize the changes which may be responsible for the reduced transgene expression under oxidative stress conditions, LC-MS-based reduced peptide mapping analysis was performed to achieve site-specific PTM quantitation. As depicted in Fig. 1 B, treatment with 1000 ppm H₂O₂ resulted in over 90% oxidation at several methionine residues, including M204, M212, and M561. M204 is part of the extended sequences of VP1 and VP2, while M212 is in the N-terminal region of VP3. M561 is shared by all three capsid proteins, positioned on the surface of the three-fold protrusion, and exhibits limited solvent accessibility (Fig. 5 A). Additionally, elevated methionine oxidation was observed at M374 (from 1.5% to 26%), M405 (from 0.2% to 13%), and M637 (from 0.4% to 16%) (Fig. 1 B and Supplemental Table 1 ). These residues are either minimally solvent-accessible or buried within the native capsid structure (23) consistent with their relatively low oxidation levels under strong oxidative stress conditions. Mild oxidative stress (i.e., 1 ppm H 2 O 2 ) induced similar changes in methionine oxidation, although to a much lesser extent (Fig. 1 B). As the transgene expression remained stable under mild oxidative stress compared to the control, it was concluded that moderate oxidation (M204 from 1.3% to 10.1% and M212 from 1.3% to 8.9%) of these methionine residues ( Supplemental Table 1 ) did not significantly impact AAV biological activity. Finally, no significant changes in other PTM, including asparagine deamidation, aspartic acid isomerization, VP protein N-terminal acetylation, and serine/threonine phosphorylation, were observed under either strong or mild oxidative stress conditions (data not shown). Previous studies have reported that oxidative modifications in therapeutic proteins often lead to alteration in higher-order structures, promote aggregate formation, and generate products with potentially reduced biological activity ( 24 – 26 ). To understand whether physical degradation occurred alongside chemical modifications in the AAV8 samples under oxidative stress and contributed to the observed reduction in transgene expression various analytical techniques as described above were utilized. Despite the particle size remained consistent under strong oxidative stress conditions (Fig. 1 C), SEC analysis revealed up to approximately 10% loss in monomeric AAV8 recovery, indicating that capsid titer loss may be attributed to the surface adsorption of denatured AAV8 products onto the container-closure system (Fig. 1 D). Meanwhile, the increasing levels of oxidative stress were associated with a trend of decreasing vector genome titer, with up to ~ 15% reduction observed under 1000 ppm H₂O₂ treatment (Fig. 1 E). This decline was accompanied by a corresponding increase in free DNA levels, rising from ~ 0.3% to 1.8% (Fig. 1 F). These observations may be attributed to conformational instability of AAV8 capsid under oxidative stress, potentially driven by oxidation-induced conformational changes in structure, which in turn leads to the release of genomic DNA. The methionine oxidation profile further reveals capsid structural changes under oxidative stress, as maximum oxidation of M204 and M212 coincides with extensive oxidation of other methionine residues, including nearly complete oxidation of M561. Importantly, M561 is largely inaccessible to solvent in the native state (Fig. 5 A), suggesting that additional structural rearrangements are necessary for it to become susceptible to oxidation. Interestingly, a prior study identified the critical role of M203 and M211 in capsid assembly. Point mutation of these two methionine residues to Leu led to failed capsid production. Therefore, it is reasonable to hypothesize that the near-complete oxidation of these two methionine residues under strong oxidative stress conditions may significantly destabilize the capsid structure, thereby facilitating the DNA release ( 27 ). The stoichiometry of viral proteins was also analyzed, revealing that both the control and 1 ppm H₂O₂ treated samples exhibited a VP1:VP2:VP3 ratio of approximately 1:1.7:10.4 ( Fig. 1 G), consistent with the commonly reported VP molar ratio of approximately 1:1:10 for AAVs demonstrating good transduction efficiency ( 28 , 29 ). However, exposure of AAV8 to 1000 ppm H₂O₂ resulted in a noticeable change in viral protein stoichiometry, with the VP3 ratio increasing from 10.4 to 12.2 (Fig. 1 G). This suggests fragmentation of capsids may occur under strong oxidative stress conditions, resulting in increased VP3 ratio. The data collectively suggests both chemical and physical degradation pathways occur under oxidative stress. Alterations in the transgene expression of AAV8 are likely to be attributed to the combination effect from methionine oxidation on capsid proteins, genomic DNA leakage caused by oxidation-induced capsid conformational change and instability, reduction of capsid titer due to associated surface adsorption, as well as increased VP3 ratio as a result of fragmentation of capsid under strong oxidative stress. Stability Changes of AAV8 Under pH Stress The pH-dependent degradation behavior of AAV8 was evaluated under extreme acidic and basic conditions to simulate potential exposures during the drug substance manufacturing process. Specifically, AAV8 was dialyzed into respective buffers at pH 3.0 and pH 9.0, followed by incubation at 25°C for up to seven days. A buffer at neutral pH (7.3) was used as a control. Consistent with prior findings that AAV8 and AAV9 lose transduction efficiency under highly acidic conditions ( 30 – 32 ), our results revealed a substantial reduction in transgene expression in AAV8 following seven days of incubation at pH 3.0 (Fig. 2 A). In contrast, transgene expression levels in the AAV8 samples incubated at pH 9.0 remained comparable to those observed in the control buffer at pH 7.3 (Fig. 2 A). A comprehensive PTM analysis revealed that AAV8 exhibited increased asparagine deamidation at pH 9.0, with levels at N57, N94, and N263 reaching approximately 38%,5%, and 29%, respectively (Fig. 2 B). Notably, N57 and N94 are located at VP1u region, whereas N263 is surface-exposed (Fig. 5 C) and situated in the region shared by all three capsid proteins. Although these asparagine deamidations were found to be critical for AAV8 transduction efficiency in a previous report using point mutation analysis ( 33 ), our results showed that moderate increases in deamidation at N57, N94 and N263, induced by pH 9.0 stress, did not significantly affect AAV8 transgene expression. This discrepancy is likely due to differences in deamidation levels: point mutations result in 100% change, whereas real-life stress typically induces only moderate levels. Therefore, AAV capsids may exhibit greater tolerance to deamidation than previously understood, or the impact of deamidation might vary based on the specific residues involved within the capsid structure. Furthermore, isomerization analysis revealed minor changes under acidic condition at D4, D220, and D628, with increases from approximately 3% to 9%, 5% to 7%, and 2.5% to 3.1%, respectively (Fig. 2 C). The increased isomerization observed under pH 3.0 stress, compared to neutral pH and pH 9.0, aligns with the mechanism of this modification, as slightly acidic conditions facilitate the formation of succinimide, the intermediate product in Asp isomerization. No other notable PTM changes were detected under pH 9.0 and 3.0 conditions. These findings indicate that, although extreme pH conditions can induce chemical modifications in AAV capsid proteins, such modifications generally occur at low levels at room temperature over reasonably short durations (e.g., up to 7 days). Subsequently, we investigated whether physical degradation of AAV8 contributes to the observed reduction in AAV8 transgene expression under pH 3.0 stress condition. We observed that, at pH 3.0, the particle size of AAV8 increased from approximately 25 nm to 44 nm immediately after dialysis and further expanded to approximately 65 nm after 7 days of incubation at pH 3.0, indicating the formation of large AAV8 aggregates (Fig. 2 D). In contrast, the particle size of AAV8 remained stable at pH 9.0 or 7.3 throughout the 7-day incubation period. Interestingly, SEC analysis revealed negligible changes in monomeric AAV recovery under both pH 3.0 and pH 9.0 conditions (Fig. 2 E). This suggests the large aggregates detected at pH 3.0 by DLS may be reversible under the running condition of SEC. Thus, the stability-indicating capability of SEC for detecting and quantifying AAV aggregates remains to be further evaluated. Additionally, a slight reduction in vector genome titer was observed under both pH 3.0 and pH 9.0 conditions, with decreases of 13% and 9%, respectively (Fig. 2 F). Free DNA levels in the AAV8 sample increased from 0.4% to 1.3% immediately after dialysis into the pH 3.0 buffer, with no further increase observed after the 7-day incubation at pH 3.0 (Fig. 2 G). Similar genomic DNA leakage from viral particles at pH 4.0 has been reported for AAV2 and AAVv66 ( 34 ). Viral protein stoichiometry analysis revealed that the VP3 ratio increased from 10.5 to 11.4 at pH 9.0 and to 11.9 at pH 3.0, while the VP2 ratio decreased from 1.7 to 1.5 and 1.3, respectively (Fig. 2 H). This suggests high pH up to 9.0 and low pH near 3.0 may induce capsid fragmentation. Exposure of AAVs to these extreme pH conditions during the manufacturing process should be carefully controlled or minimized when possible. In summary, our findings indicate that during the drug substance manufacturing process, AAV8 may maintain acceptable stability and quality under strong basic conditions but is susceptible to degradation under strong acidic conditions. The degradations likely involve both chemical and physical pathways, with aggregation being the major contributor to the loss of AAV8 biological activity in strong acidic environments. Stability Changes of AAV8 Under 40°C and 45°C The impact of thermal stress on AAV8 was assessed by exposing AAV8 to elevated temperatures for durations of up to four weeks. The onset temperature for vector genome DNA release (T onset ) of AAV8 in the optimized AAV8 formulation, determined using DSF, was approximately 50°C (Fig. 3 A), and was used to guide the selection of stress temperatures. To ensure sufficient generation of degradation products and to understand the differential effect of temperature on AAV8, two stress temperatures of 40°C and 45°C were assessed in this study following the general rule of thumb that the selected thermal stress temperature should stay below T onset and at least 10°C to 20°C below T m ( 35 ). As illustrated in Fig. 3 B, subjecting AAV8 to up to 4 weeks of incubation at 40°C and 45°C resulted in a drastic decrease in transgene expression, demonstrating a temperature-dependent effect on impacting AAV stability. After 4 weeks, the transgene expression in the AAV8 sample was greatly reduced at 40°C and completely abolished at 45°C. High temperature incubation also led to extensive chemical modifications on AAV8 capsid proteins. After incubating AAV8 at 40°C and 45°C for 4 weeks, increased aspartic acid isomerization was detected at D4 (from 3% to 24% and 43%), D69 (from 0.3% to 4% and 11%), and D220 (from 5% to 19% and 27%) (Fig. 3 C). Elevated asparagine deamidation was observed at N57 (from 18% to 50% and 82%), N94 (from 2% to 21% and 56%), and N263 (from 14% to 35% and 53%) (Fig. 3 D). Additionally, methionine oxidation increased notably at M204 (from ~ 8% to 15%), M212 (from ~ 9% to 17%), and M212* (from ~ 5% to 12%) (Fig. 3 E). Consistent with previous findings, the VP1u, VP1/2, and VP3 N-terminus regions were identified as hotspots for PTM formation under thermal stress ( 20 ). The VP1u externalization under heat shock, along with its unstructured conformation, may provide a plausible explanation for the accelerated deamidation at N57 and N94 and isomerization at D4 and D69 ( 7 ). Additionally, a recent hydrogen/deuterium exchange mass spectrometry study analyzed AAV8 incubated at 60°C and revealed increased deuterium uptake in the five-fold axis region, specifically in a polypeptide sequence spanning residues A205 to W229 ( 36 ). The increased structure dynamics of this region under thermal stress correlated with the accelerated formation of oxidation at M204 and M212, as well as isomerization at D220 (Fig. 5 B). Finally, the extended levels of deamidation at N263 under thermal stress are attributed to its high solvent accessibility and favorable Asn-Gly motif, consistent with previous reports ( 33 ). Moreover, our results showed that the rate of PTM formation in AAV8 accelerates at 45°C compared to 40°C, correlating with reduced transgene expression at 45°C. Interestingly, prior studies conducted under 1 ppm H 2 O 2 oxidative stress and pH 9.0 stress revealed that moderate levels of Met oxidation and Asn deamidation did not significantly affect biological activity of AAV8, indicating that other degradation pathways may also play a role. It is well known that therapeutic proteins are prone to extended exposure at high temperatures, which may induce conformational changes resulting in physical instability and/or reduced biological activity ( 37 ). Aligning with previous reports ( 38 , 39 ), our results showed that the particle size of AAV8, as measured by DLS, increased from 26 nm to 31 nm and 62 nm after 4 weeks at 40°C and 45°C, respectively (Fig. 3 F). This was accompanied by a significant loss in monomeric AAV recovery, as revealed by SEC analysis, which showed reductions of ~ 75% and 26% after the 4-week incubation at 40°C and 45°C, respectively (Fig. 3 G). These results indicate, unlike the AAV aggregates formed under pH 3.0 condition, the large AAV aggregates formed after extended exposure at high temperatures might be due to profound and extensive conformational changes. It is likely these aggregates remain irreversible under the SEC running conditions and thus cannot enter the SEC column. Concurrently, a significant reduction in vector genome titer (Fig. 3 H) and an increase in free DNA (Fig. 3 I) were also observed, especially at 45°C. To assess the impact of vector genome DNA release on genome titer loss, genome titers of the AAV8 samples stressed at 40°C and 45°C were also measured without DNase I digestion prior to capsid denaturation. We found omitting DNase I digestion improved genome titer recovery from 40% to 75% for AAV8 incubated at 45°C for 4 weeks ( Supplemental Fig. 1A and 1B ) supporting the presence of externalized DNA. Free DNA-mediated capsid aggregation, along with the subsequent sample loss due to either precipitation or surface adsorption, likely accounts for the remaining genome titer loss. In addition, thermal stress resulted in substantial alterations in viral protein ratios. The VP3 ratio increased from 10.3 to 12.1 at 40°C and 16.3 at 45°C, while the VP2 ratio rose from 1.6 to 1.8 and 2.5, respectively (Fig. 3 J). This suggests fragmentation of capsids occurs under these thermal stress conditions, especially at 45°C. Altogether, our study revealed that several physical degradation pathways of AAV8 including capsid aggregation, genome DNA release, viral protein fragmentation, and associated surface adsorption, are triggered by high-temperature stress. Additionally, we observed a significant difference in the extent of physical degradation at 40°C versus 45°C, indicating that AAV8 capsids might lose structural integrity at temperatures approaching the T onset temperature of 50°C in this formulation. It is clear a combination effect of both chemical and physical degradations of AAV8 accounts for the reduction of biological activity under thermal stress. Stability Changes of AAV8 Under Freeze-Thaw and Agitation Stress AAV8 was subjected to two and four freeze-thaw cycles between − 80°C and room temperature, or vortexing at 1000 rpm for durations of 60 minutes and 120 minutes, to assess its degradation profile under freeze-thaw and agitation stress conditions. Our results showed that no meaningful changes to the AAV8 transgene expression, particle size distribution, vector genome titer, recovery of monomeric AAV8 capsids, and viral protein ratio were detected in the freeze-thaw or agitation stressed samples (Fig. 4 A to 4 E). These results indicate that neither chemical nor physical degradations of AAV8 occurred in the base formulation under the freeze-thaw and agitation stress conditions assessed in this study. Discussion In this work, we performed a comprehensive forced degradation study of AAV8 by applying various types of stresses which might be encountered during AAV manufacturing, storage, shipping and handling, but exceeding the conditions commonly used for stability assessment. Our goal is to gain an in-depth understanding of the major degradation pathways under each type of stress and recommend CQAs of AAV to monitor and control during manufacturing, product release, and stability testing. Performing such a study is particularly important in the case of AAV gene therapy drug development due to the complexity of their molecular structure and the limited prior knowledge about the potential influence of these stresses on the product attributes of various AAV serotypes. Although the degradation products generated from forced degradation studies may not be formed under relevant manufacturing, storage, and in-use conditions, the result of the study provides critical insight into developing stability-indicating assays, designing effective strategies for manufacturing, formulation, and drug product processes, as well as establishing the product degradation profiles for comparability assessment. In this study, we employed various analytical techniques capable of detecting and quantifying the different types of degradation products that may alter the sequence, structure, concentration, purity, or biological activity of the stressed AAV8 samples. Comprehensive and appropriate characterization of the biochemical, biophysical, and biological properties of these samples is an essential part for a well-designed forced degradation study for achieving a thorough understanding of the chemical and physical degradation mechanisms of the product. While LC-MS/MS was found sufficient for characterizing the site-specific chemical modifications in stressed AAV8 samples, the complexity of physical degradation mechanisms for AAVs and our evolving understanding of preliminary critical quality attributes necessitated the use of a large and diverse set of assays to monitor the stability-indicating preliminary critical quality attributes. These assays include vector genome titer by ddPCR, aggregation or particle size distribution by DLS, monomeric AAV capsid recovery by SEC, free DNA by dye-binding assay, viral protein ratio by microfluidic electrophoresis, and transgene protein expression by cell-based assay. Indeed, these assays allow us to form a much more complete picture of the degradation pathways of AAV8 which occur under the various modes of stress. Many of the degradation pathways identified in this study either failed to be revealed or analyzed to the same extent in detail in previously reported forced degradation studies of other AAV serotypes ( 13 , 31 , 39 ). Furthermore, our results showed the assays used in this study demonstrated sufficient sensitivity and good performance for detecting and quantifying the AAV8 degradation products and have great potential to be established in a quality control setting as stability-indicating release assays to support AAV product release and shelf-life stability testing. By exposing AAV8 to commonly used forced degradation conditions including oxidation, high and low pH, high temperature, freeze-thaw, and agitation stress, we have identified the major chemical degradation pathways of AAV8 are methionine oxidation, asparagine deamidation, and aspartic acid isomerization ( Table 2 ). The major physical degradation pathways of AAV8 include aggregation, genome DNA leakage, viral protein fragmentation, and associated surface adsorption potentially due to conformational changes in capsids and/or aggregation ( Table 2 ). Specifically, strong oxidative stress causes significant methionine oxidation on AAV8 capsid proteins. This likely induces conformational change in the capsids, which subsequently induces genome DNA leakage, fragmentation of viral proteins, and associated surface adsorption. As a result, a substantial reduction of AAV8 transgene expression was observed under strong oxidative stress. In contrast, chemical degradations are not the major degradation pathway for AAV8 under pH stress. We found that AAV8 maintains acceptable stability and quality in our previously developed formulation under strong basic conditions but is susceptible to physical degradation under strong acidic conditions. Extreme low pH causes formation of large AAV8 aggregates and accelerates viral protein fragmentation, which are likely to be the major degradation pathways underlying the loss of AAV8 transgene expression at pH 3.0. Our study also revealed that high temperature stress accelerates various chemical and physical degradation pathways. Exposure of AAV8 at 40°C and 45°C after 4 weeks led to significantly elevated aspartic acid isomerization and asparagine deamidation, as well as a notable increase in methionine oxidation. Extensive aggregation, viral protein fragmentation, and genome DNA leakage were also observed under high temperature stress. The combination effect from these changes caused drastic abolishment of AAV8 transgene expression in a temperature-dependent manner. In addition, we observed a surprisingly large difference in the extent of chemical and physical degradation at 40°C versus 45°C, indicating AAV8 capsids might lose structural integrity at temperatures approaching the T onset temperature of 50°C in this formulation. Under the freeze-thaw and agitation stress conditions evaluated in this study, minimal degradation of AAV8 such as aggregation or particulate formation was observed, indicating the formulation factors we selected for AAV8 including pH, ionic strength, composition and concentration of cryoprotection, and surfactant are sufficient to protect AAV8 against the interfacial stress and phase separation occurred under the conditions evaluated in this study, thus maintaining good stability. It is worthwhile to mention that the formulation conditions selected for forced degradation studies could influence the study results because pH, ionic strength, as well as the composition and concentration of each excipient in the formulation may impact chemical stability and/or physical stability of a protein, with the latter mainly attributed to influence on colloidal stability of the protein ( 40 , 41 ). This protective effect may contribute to the mild changes observed in oxidation and transgene expression of AAV8 when exposed to 1 ppm H 2 O 2 , or it is possible that the degree of methionine oxidation did not reach the threshold required to compromise capsid stability. In addition, a standardized AAV manufacturing process has yet to be developed so far due to many practical challenges such as the complexity of the molecular structure of AAV, the fact that variations in AAV capsid structure and serotype may demand changes in the production and/or purification process, and most importantly, the intrinsic heterogenous nature of AAV rendering high-resolution separation of empty, partial, and full capsids extremely difficult especially during large-scale clinical manufacturing process. Consequently, AAVs from different resources not only vary in AAV serotypes or capsid structure, transgene sequence, format, or length, they could also have different levels of chemical modifications, purity, or impurity profiles. These differences may have an impact on the quality and/or stability of the AAV products. Given the absence of well-established standardized analytics for AAV characterization and definition of CQAs for AAV, caution should be taken when analyzing and interpreting results from different forced degradation studies reported in literature. In summary, our study has elucidated how AAV8 degrades under various stress conditions. These findings are likely applicable to other AAV serotypes as the capsid protein sequences and structure are highly conserved among certain serotypes. In addition, the knowledge gained from this study can accelerate analytical, formulation, and process development efforts, supporting the establishment of robust manufacturing process and the production of safe and efficacious AAV gene therapy products. Declarations Data Availability Statement The data supporting the findings of this study are available from the corresponding author upon request. Ethical Approval No animal studies were conducted in this study. Competing Interests The authors declare no competing interests. Funding The work presented in this manuscript was funded by Regeneron Pharmaceuticals, Inc. All authors are full-time employees and shareholders of Regeneron Pharmaceuticals, Inc. Author Contributions Conceptualization: KYL, SN, SW, LZ, data acquisition and analysis: YCC, KYL, SN, TNT, ST, YH, YY, SM, HAR, AH, NL, MR, writing, review and editing: KYL, SN, LZ, SW, DL, NL, MS, supervision: DL, NL, MS. Acknowledgements The authors acknowledge Zhe Zhang, Sheldon Mink, and Andrew Tustian at Viral Production Core for providing AAV8. References Wang J-H, Gessler DJ, Zhan W, Gallagher TL, Gao G. Adeno-associated virus as a delivery vector for gene therapy of human diseases. Signal Transduct Target therapy. 2024;9(1):78. Suarez-Amaran L, Song L, Tretiakova AP, Mikhail SA, Samulski RJ. AAV vector development, back to the future. Mol Ther. 2025;33(5):1903–36. Wörner TP, Bennett A, Habka S, Snijder J, Friese O, Powers T, et al. Adeno-associated virus capsid assembly is divergent and stochastic. Nat Commun. 2021;12(1):1642. Large EE, Silveria MA, Zane GM, Weerakoon O, Chapman MS. Adeno-associated virus (AAV) gene delivery: dissecting molecular interactions upon cell entry. Viruses. 2021;13(7):1336. Girod A, Wobus CE, Zádori Z, Ried M, Leike K, Tijssen P, et al. The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity. J Gen Virol. 2002;83(5):973–8. Agbandje-McKenna M, Kleinschmidt J. AAV capsid structure and cell interactions. Adeno-associated virus: methods protocols. 2011:47–92. Kronenberg S, Böttcher B, von der Lieth CW, Bleker S, Kleinschmidt JA. A conformational change in the adeno-associated virus type 2 capsid leads to the exposure of hidden VP1 N termini. J Virol. 2005;79(9):5296–303. Venkatakrishnan B, Yarbrough J, Domsic J, Bennett A, Bothner B, Kozyreva OG, et al. Structure and dynamics of adeno-associated virus serotype 1 VP1-unique N-terminal domain and its role in capsid trafficking. J Virol. 2013;87(9):4974–84. Bleker S, Sonntag F, Kleinschmidt JA. Mutational analysis of narrow pores at the fivefold symmetry axes of adeno-associated virus type 2 capsids reveals a dual role in genome packaging and activation of phospholipase A2 activity. J Virol. 2005;79(4):2528–40. Raupp C, Naumer M, Müller OJ, Gurda BL, Agbandje-McKenna M, Kleinschmidt JA. The threefold protrusions of adeno-associated virus type 8 are involved in cell surface targeting as well as postattachment processing. J Virol. 2012;86(17):9396–408. Grossen P, Koukelli IS, van Haasteren J, Machado AH, Dürr C. The ice age–A review on formulation of Adeno-associated virus therapeutics. Eur J Pharm Biopharm. 2023;190:1–23. Liu H, Ponniah G, Zhang H-M, Nowak C, Neill A, Gonzalez-Lopez N, et al. editors. vitro and in vivo modifications of recombinant and human IgG antibodies. Taylor & Francis; 2014. MAbs. Rodriguez A, Jalimarada-Shivakumar S, Banazadeh A, Afroz S, Ali A, Deng K, et al. Insight into the degradation pathways of an AAV9. J Pharm Sci. 2024;113(9):2967–73. Bee JS, O'Berry K, Zhang YZ, Phillippi MK, Kaushal A, DePaz RA, et al. Quantitation of trace levels of DNA released from disrupted adeno-associated virus gene therapy vectors. J Pharm Sci. 2021;110(9):3183–7. Xu Y, Jiang B, Samai P, Tank S-M, Shameem M, Liu D. Genome DNA leakage of adeno–associated virus under freeze–thaw stress. Int J Pharm. 2022;615:121464. Li S, Wang X, Lai K-Y, Wert J, Zhi L, Shameem M et al. Development of an optimized SEC method for characterization of genome DNA leakage from adeno-associated virus products. Anal Bioanal Chem. 2024:1–10. Ye X, Hu M, Hu Y, Qiu H, Li N. HDX-MS reveals pH and temperature-responsive regions on AAV capsids and the structural basis for DNA release. Gene Ther. 2025:1–11. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27:544–75. Som M, Gikanga B, Kanapuram V, Yadav S. Drug product formulation and fill/finish manufacturing process considerations for AAV-based genomic medicines. J Pharm Sci. 2024. Xing T, Li S, Tang S, Huang Y, Liu G, Yan Y, et al. Distinct chemical degradation pathways of AAV1 and AAV8 under thermal stress conditions revealed by analytical anion exchange chromatography and LC-MS-based peptide mapping. J Pharm Biomed Anal. 2024;251:116452. Ali D, Peláez SS, Lemazurier T, Schroeter A, Adler M, Bong J, et al. Vaporized Hydogen Peroxide Uptake by Tubing used for Aseptic Fill-Finish Manufacturing of Biopharmaceutical Drug Products. Eur J Pharm Biopharm. 2025;207:114618. Halley J, Chou YR, Cicchino C, Huang M, Sharma V, Tan NC, et al. An industry perspective on forced degradation studies of biopharmaceuticals: survey outcome and recommendations. J Pharm Sci. 2020;109(1):6–21. Nam H-J, Lane MD, Padron E, Gurda B, McKenna R, Kohlbrenner E, et al. Structure of adeno-associated virus serotype 8, a gene therapy vector. J Virol. 2007;81(22):12260–71. Kerwin BA, Remmele RL Jr. Protect from light: photodegradation and protein biologics. J Pharm Sci. 2007;96(6):1468–79. Liu D, Ren D, Huang H, Dankberg J, Rosenfeld R, Cocco MJ, et al. Structure and stability changes of human IgG1 Fc as a consequence of methionine oxidation. Biochemistry. 2008;47(18):5088–100. Torosantucci R, Schöneich C, Jiskoot W. Oxidation of therapeutic proteins and peptides: structural and biological consequences. Pharm Res. 2014;31:541–53. Warrington KH Jr, Gorbatyuk OS, Harrison JK, Opie SR, Zolotukhin S, Muzyczka N. Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus. J Virol. 2004;78(12):6595–609. McColl-Carboni A, Dollive S, Laughlin S, Lushi R, MacArthur M, Zhou S, et al. Analytical characterization of full, intermediate, and empty AAV capsids. Gene Ther. 2024;31(5):285–94. Zhang Z, Park J, Barrett H, Dooley S, Davies C, Verhagen MF. Capillary electrophoresis-sodium dodecyl sulfate with laser-induced fluorescence detection as a highly sensitive and quality control-friendly method for monitoring adeno-associated virus capsid protein purity. Hum Gene Ther. 2021;32(11–12):628–37. Lowell JA, Mah KM, Bixby JL, Lemmon VP. AAV8 transduction capacity is reduced by prior exposure to endosome-like pH conditions. Neural regeneration Res. 2021;16(5):851–5. Lengler J, Gavrila M, Brandis J, Palavra K, Dieringer F, Unterthurner S, et al. Crucial aspects for maintaining rAAV stability. Sci Rep. 2024;14(1):27685. Potter M, Lins B, Mietzsch M, Heilbronn R, Van Vliet K, Chipman P et al. A simplified purification protocol for recombinant adeno-associated virus vectors. Mol Therapy Methods Clin Dev. 2014;1. Giles AR, Sims JJ, Turner KB, Govindasamy L, Alvira MR, Lock M, et al. Deamidation of amino acids on the surface of adeno-associated virus capsids leads to charge heterogeneity and altered vector function. Mol Ther. 2018;26(12):2848–62. Hsu H-L, Brown A, Loveland AB, Lotun A, Xu M, Luo L, et al. Structural characterization of a novel human adeno-associated virus capsid with neurotropic properties. Nat Commun. 2020;11(1):3279. van Maarschalkerweerd A, Wolbink G-J, Stapel SO, Jiskoot W, Hawe A. Comparison of analytical methods to detect instability of etanercept during thermal stress testing. Eur J Pharm Biopharm. 2011;78(2):213–21. Yamaguchi Y, Shimojo S, Ikeda T, Fukuhara M, Tsunaka Y, Shibuya R, et al. Unfolding of viral protein 1 N-termini facilitates genome ejection from recombinant adeno-associated virus serotype 8. Molecular Therapy Methods & Clinical Development; 2025. Nowak C, Cheung K, Dellatore JM, Katiyar S, Bhat A, Sun R J, et al. editors. Forced degradation of recombinant monoclonal antibodies: A practical guide. Taylor & Francis; 2017. MAbs. Jarand CW, Baker K, Petroff M, Jin M, Reed WF. DNA released by adeno-associated virus strongly alters capsid aggregation kinetics in a physiological solution. Biomacromolecules. 2024;25(5):2890–901. Kumar P, Wang M, Kumru OS, Hickey JM, Sanmiguel J, Zabaleta N, et al. Correlating physicochemical and biological properties to define critical quality attributes of a rAAV vaccine candidate. Mol Therapy Methods Clin Dev. 2023;30:103–21. Wang W, Nema S, Teagarden D. Protein aggregation—Pathways and influencing factors. Int J Pharm. 2010;390(2):89–99. Mahler H-C, Friess W, Grauschopf U, Kiese S. Protein aggregation: pathways, induction factors and analysis. J Pharm Sci. 2009;98(9):2909–34. Tables Tables 1 to 2 are available in the Supplementary Files section. Additional Declarations There is NO conflict of interest to disclose. Supplementary Files SupplementalTable1.xlsx Supplemental Table 1 PTM profile of AAV8 under oxidative stress. The asterisk indicates a residue located in the unique N-terminal peptides of the VP3 protein. SupplementalTable2.xlsx Supplemental Table 2 PTM profile of AAV8 under pH stress. The asterisk indicates a residue located in the unique N-terminal peptides of the VP3 protein. SupplementalTable3.xlsx Supplemental Table 3 PTM profile of AAV8 under thermal stress. The asterisk indicates a residue located in the unique N-terminal peptides of the VP3 protein. SupplementalFigure1.jpg Supplemental Figure 1 Impact of DNaseI digestion on vector genome titer recovery of AAV8 after thermal stress at 40°C (A) and 45°C (B). Table1.xlsx Table 1 Summary of stress conditions utilized in AAV8 forced degradation study Table2.xlsx Cite Share Download PDF Status: Published Journal Publication published 12 Feb, 2026 Read the published version in Gene Therapy → Version 1 posted Editorial decision: revise 10 Nov, 2025 Review # 2 received at journal 23 Oct, 2025 Review # 1 received at journal 14 Oct, 2025 Reviewer # 2 agreed at journal 03 Oct, 2025 Reviewer # 1 agreed at journal 01 Oct, 2025 Reviewers invited by journal 28 Sep, 2025 Editor assigned by journal 12 Sep, 2025 Submission checks completed at journal 12 Sep, 2025 First submitted to journal 12 Sep, 2025 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-7596388","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":521849228,"identity":"b0c0d09b-14c1-4a67-9254-46cd119278de","order_by":0,"name":"Li Zhi","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA0UlEQVRIiWNgGAWjYBACPmYGBmYGAxsStLBBtKSRooUBpIXhMCla2BmYPxcUnM/n51987MHHPTZ5DOyHj24g5DDjGQa3LWfOeJZuOONZWjEDT1raDUJaknkMbhsY3DhjJs1z4HBigwSPGUEth3kMzhnY3zj/TfoPkVoYm3kMDhgY8PewSTMQp4WxmZnHINlA4gabmWTPgbTENkJ+4ec/fPgzzx87A/7+w88kfhywSexnP3wMrxYGBsYGCC2RALUXv3IU+w4Qr3YUjIJRMApGFgAAgW9AkoEmc5gAAAAASUVORK5CYII=","orcid":"","institution":"REGENERON","correspondingAuthor":true,"prefix":"","firstName":"Li","middleName":"","lastName":"Zhi","suffix":""},{"id":521849229,"identity":"761beafb-9f8d-4eaa-b6b0-4c1a4be61e3c","order_by":1,"name":"Kuan-Yu Lai","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Kuan-Yu","middleName":"","lastName":"Lai","suffix":""},{"id":521849230,"identity":"6d92bea8-5f8b-4d5d-ab81-f4675e698663","order_by":2,"name":"Song Nie","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Song","middleName":"","lastName":"Nie","suffix":""},{"id":521849231,"identity":"b9e5e878-0207-4f00-85a6-a5c3caf01cae","order_by":3,"name":"Yu-Chieh (Ariel) Chen","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Yu-Chieh","middleName":"(Ariel)","lastName":"Chen","suffix":""},{"id":521849232,"identity":"0834e7d0-2644-4f91-a0bb-7db02a29f3b5","order_by":4,"name":"Timothy Tiambeng","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Timothy","middleName":"","lastName":"Tiambeng","suffix":""},{"id":521849233,"identity":"0dcc7475-1c84-4b50-aba8-efcfe7fe6c8d","order_by":5,"name":"Shuli Tang","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Shuli","middleName":"","lastName":"Tang","suffix":""},{"id":521849234,"identity":"b4ac698b-3bc7-43c7-9246-d1695da2a69b","order_by":6,"name":"Yu Huang","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Yu","middleName":"","lastName":"Huang","suffix":""},{"id":521849235,"identity":"75f008a5-1b32-4579-bafd-82f428a77580","order_by":7,"name":"Yuetian Yan","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Yuetian","middleName":"","lastName":"Yan","suffix":""},{"id":521849236,"identity":"1f2f236e-2059-46ee-b030-589bfee37c50","order_by":8,"name":"Shashwat Mishra","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Shashwat","middleName":"","lastName":"Mishra","suffix":""},{"id":521849237,"identity":"396d1fda-44be-4cd7-99a9-d32ff8ae06bb","order_by":9,"name":"Humam Al-Rubaye","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Humam","middleName":"","lastName":"Al-Rubaye","suffix":""},{"id":521849238,"identity":"2131b28c-1298-434b-b399-ac0607fcae7e","order_by":10,"name":"Aynur Hermann","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Aynur","middleName":"","lastName":"Hermann","suffix":""},{"id":521849239,"identity":"031b32c2-8bb4-4e6d-bf69-0ff48178a59b","order_by":11,"name":"Nina Liu","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Nina","middleName":"","lastName":"Liu","suffix":""},{"id":521849240,"identity":"132bf624-631e-4145-a63f-9bc9ed6cfa45","order_by":12,"name":"Michael Rosconi","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Michael","middleName":"","lastName":"Rosconi","suffix":""},{"id":521849241,"identity":"ff8367bd-7982-49ca-a9a6-92ed69e6e156","order_by":13,"name":"Ning Li","email":"","orcid":"","institution":"Regeneron","correspondingAuthor":false,"prefix":"","firstName":"Ning","middleName":"","lastName":"Li","suffix":""},{"id":521849242,"identity":"98286f04-e33a-4f38-9b1b-10060cb7c3e8","order_by":14,"name":"Mohammed Shameem","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Mohammed","middleName":"","lastName":"Shameem","suffix":""},{"id":521849243,"identity":"5eff37ac-5431-4d8a-92c7-5c478f2b16dd","order_by":15,"name":"Shunhai Wang","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Shunhai","middleName":"","lastName":"Wang","suffix":""},{"id":521849244,"identity":"c81e20b3-5e9f-40c0-8948-1f5b98a050d9","order_by":16,"name":"Dingjiang Liu","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Dingjiang","middleName":"","lastName":"Liu","suffix":""}],"badges":[],"createdAt":"2025-09-12 04:35:15","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-7596388/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-7596388/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1038/s41434-026-00593-6","type":"published","date":"2026-02-12T05:00:00+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":93164705,"identity":"57a166c7-9d26-445c-90cf-3599a356ca1d","added_by":"auto","created_at":"2025-10-09 17:40:45","extension":"jpg","order_by":0,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":2489636,"visible":true,"origin":"","legend":"","description":"","filename":"Figure1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7596388/v1/18d2444b3fdea379e7a59da6.jpg"},{"id":93164713,"identity":"5ae6d472-a59b-41c6-832b-c830e43af1d4","added_by":"auto","created_at":"2025-10-09 17:40:45","extension":"docx","order_by":1,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":149154,"visible":true,"origin":"","legend":"","description":"","filename":"ManuscriptComprehensiveForcedDegradationStudyRevealingDiverseChemicalandPhysicalDegradationPathwaysofAAV8Final.docx","url":"https://assets-eu.researchsquare.com/files/rs-7596388/v1/77b55f20e1427908c8ec9d2a.docx"},{"id":93164726,"identity":"63bc95f3-9579-44c8-892b-7868b9c58ae0","added_by":"auto","created_at":"2025-10-09 17:40:45","extension":"jpg","order_by":2,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":2682773,"visible":true,"origin":"","legend":"","description":"","filename":"Figure2.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7596388/v1/62d72b3c7352069060660f85.jpg"},{"id":93165329,"identity":"99585084-14fe-4382-9e31-2187365ecadf","added_by":"auto","created_at":"2025-10-09 17:48:45","extension":"xlsx","order_by":3,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":12276,"visible":true,"origin":"","legend":"","description":"","filename":"SupplementalTable2.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-7596388/v1/e82683461a1c256655b14836.xlsx"},{"id":93164718,"identity":"2a3c72ff-7dd5-4ead-b340-11771d4866ef","added_by":"auto","created_at":"2025-10-09 17:40:45","extension":"jpg","order_by":4,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":3207117,"visible":true,"origin":"","legend":"","description":"","filename":"Figure3.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7596388/v1/31c8ea0edf0735e8926a9e92.jpg"},{"id":93165985,"identity":"ef4288f4-8897-4a7c-9c22-aec009938c1d","added_by":"auto","created_at":"2025-10-09 17:56:45","extension":"xlsx","order_by":5,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":12297,"visible":true,"origin":"","legend":"","description":"","filename":"SupplementalTable1.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-7596388/v1/e434680ce9f7f2e0c2c85216.xlsx"},{"id":93165335,"identity":"53de639a-283b-4513-b1fb-c18c0065c567","added_by":"auto","created_at":"2025-10-09 17:48:45","extension":"jpg","order_by":6,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":2173711,"visible":true,"origin":"","legend":"","description":"","filename":"Figure4.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7596388/v1/c17a3a595292d3e5667508f4.jpg"},{"id":93165990,"identity":"af21037e-6b8c-4bac-b47c-88fb08cf124d","added_by":"auto","created_at":"2025-10-09 17:56:48","extension":"xlsx","order_by":7,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":12527,"visible":true,"origin":"","legend":"","description":"","filename":"SupplementalTable3.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-7596388/v1/28517f19ab44b2aa98389a59.xlsx"},{"id":93165989,"identity":"23340334-bb7b-4c5c-962d-d2daf9f17c93","added_by":"auto","created_at":"2025-10-09 17:56:47","extension":"jpg","order_by":8,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":2952620,"visible":true,"origin":"","legend":"","description":"","filename":"Figure5.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7596388/v1/6b1d27892c55779f4d25679b.jpg"},{"id":93165337,"identity":"16df4377-caf2-4e17-a09c-5096471963ad","added_by":"auto","created_at":"2025-10-09 17:48:45","extension":"jpg","order_by":10,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":343046,"visible":true,"origin":"","legend":"","description":"","filename":"SupplementalFigure1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7596388/v1/418d30e7761234b005f6f4b0.jpg"},{"id":93165332,"identity":"a6f43ead-fde3-4277-97fd-7fb8c96fceb2","added_by":"auto","created_at":"2025-10-09 17:48:45","extension":"json","order_by":12,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":15663,"visible":true,"origin":"","legend":"","description":"","filename":"GT202500261.json","url":"https://assets-eu.researchsquare.com/files/rs-7596388/v1/c38ce77331dca748ac5af205.json"},{"id":93166291,"identity":"be13d6c7-3628-4ac8-80a6-bea3944efbb5","added_by":"auto","created_at":"2025-10-09 18:04:45","extension":"xml","order_by":13,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":127955,"visible":true,"origin":"","legend":"","description":"","filename":"GT2025002610enriched.xml","url":"https://assets-eu.researchsquare.com/files/rs-7596388/v1/5de1812410889a98f90d22a0.xml"},{"id":93165988,"identity":"1fce1d48-b234-4620-aa4f-b1cd759754c5","added_by":"auto","created_at":"2025-10-09 17:56:46","extension":"jpg","order_by":14,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":2489636,"visible":true,"origin":"","legend":"","description":"","filename":"Figure1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7596388/v1/9bd8e686afa91d16fae7b939.jpg"},{"id":93164738,"identity":"136c0fcc-dbb9-4656-bb01-e055c2a6161b","added_by":"auto","created_at":"2025-10-09 17:40:45","extension":"jpg","order_by":15,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":2682773,"visible":true,"origin":"","legend":"","description":"","filename":"Figure2.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7596388/v1/dbf6b6b5cdea7ba8465cff4d.jpg"},{"id":93164739,"identity":"072d0ff8-afc7-42fc-bbab-92e1eba2f78b","added_by":"auto","created_at":"2025-10-09 17:40:45","extension":"jpg","order_by":16,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":3207117,"visible":true,"origin":"","legend":"","description":"","filename":"Figure3.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7596388/v1/888265dded67840828f70d87.jpg"},{"id":93164735,"identity":"aedbc9f0-ea83-4e51-bb1b-cc184a4d1d41","added_by":"auto","created_at":"2025-10-09 17:40:45","extension":"jpg","order_by":17,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":2173711,"visible":true,"origin":"","legend":"","description":"","filename":"Figure4.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7596388/v1/680e3f985bb491932ba8974a.jpg"},{"id":93165986,"identity":"c10e2b1f-e908-455b-bc09-e1a0523ac72d","added_by":"auto","created_at":"2025-10-09 17:56:45","extension":"jpg","order_by":18,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":2952620,"visible":true,"origin":"","legend":"","description":"","filename":"Figure5.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7596388/v1/ebe86c0e3516aab71859c8a4.jpg"},{"id":93164723,"identity":"90a04f25-48e6-4953-b3b6-85b553f692a3","added_by":"auto","created_at":"2025-10-09 17:40:45","extension":"jpg","order_by":19,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":343046,"visible":true,"origin":"","legend":"","description":"","filename":"SupplementalFigure1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7596388/v1/b29d9677ba60190fe0dcd44e.jpg"},{"id":93164731,"identity":"874143a5-0358-45aa-9b85-4247512de92a","added_by":"auto","created_at":"2025-10-09 17:40:45","extension":"png","order_by":20,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":168032,"visible":true,"origin":"","legend":"","description":"","filename":"OnlineFigure1.png","url":"https://assets-eu.researchsquare.com/files/rs-7596388/v1/e823bf5a5db4f3094ede1021.png"},{"id":93164740,"identity":"d8cf16b1-818b-4775-bdec-2d519b2fac3d","added_by":"auto","created_at":"2025-10-09 17:40:46","extension":"png","order_by":21,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":183120,"visible":true,"origin":"","legend":"","description":"","filename":"OnlineFigure2.png","url":"https://assets-eu.researchsquare.com/files/rs-7596388/v1/4e6b9ddda052997a8017d7be.png"},{"id":93164737,"identity":"742a8620-2e2c-418e-a31c-c8c6ce8a776f","added_by":"auto","created_at":"2025-10-09 17:40:45","extension":"png","order_by":22,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":233818,"visible":true,"origin":"","legend":"","description":"","filename":"OnlineFigure3.png","url":"https://assets-eu.researchsquare.com/files/rs-7596388/v1/7e93cde7c33d5d3dfad9728f.png"},{"id":93165339,"identity":"14929969-55e3-442d-b06a-c19b395a5ef5","added_by":"auto","created_at":"2025-10-09 17:48:45","extension":"png","order_by":23,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":142202,"visible":true,"origin":"","legend":"","description":"","filename":"OnlineFigure4.png","url":"https://assets-eu.researchsquare.com/files/rs-7596388/v1/aa4ca642459dbfb2a8096c9c.png"},{"id":93164730,"identity":"c0d1cfb3-44cc-4f3f-b03e-72f04d89b2f7","added_by":"auto","created_at":"2025-10-09 17:40:45","extension":"png","order_by":24,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":460198,"visible":true,"origin":"","legend":"","description":"","filename":"OnlineFigure5.png","url":"https://assets-eu.researchsquare.com/files/rs-7596388/v1/d988764f107af57f9d58dc3c.png"},{"id":93164727,"identity":"3399f002-3a31-4b4f-bb29-1de9a6d4e676","added_by":"auto","created_at":"2025-10-09 17:40:45","extension":"png","order_by":25,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":53517,"visible":true,"origin":"","legend":"","description":"","filename":"OnlineSupplementalFigure1.png","url":"https://assets-eu.researchsquare.com/files/rs-7596388/v1/c52e12f2d8c49c6d548c25dc.png"},{"id":93165342,"identity":"d6df0aad-452e-4f51-bab0-604f68e9be2f","added_by":"auto","created_at":"2025-10-09 17:48:45","extension":"xml","order_by":26,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":125878,"visible":true,"origin":"","legend":"","description":"","filename":"GT2025002610structuring.xml","url":"https://assets-eu.researchsquare.com/files/rs-7596388/v1/ae029095f77a26bd5293fe0b.xml"},{"id":93164736,"identity":"353a2299-4ea8-4667-ba0d-8849a867fcb6","added_by":"auto","created_at":"2025-10-09 17:40:45","extension":"html","order_by":27,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":136285,"visible":true,"origin":"","legend":"","description":"","filename":"earlyproof.html","url":"https://assets-eu.researchsquare.com/files/rs-7596388/v1/775f5e03a5bb8cb3af5ad56c.html"},{"id":93164708,"identity":"0cc3fb9f-dc20-4d9a-a6b2-66db1f81cd3d","added_by":"auto","created_at":"2025-10-09 17:40:45","extension":"jpg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":2489636,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eStability Changes of AAV8 Under Oxidative Stress.\u003c/strong\u003e AAV8 samples were exposed to mild (1 ppm H\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e2\u003c/sub\u003e) and strong (1000 ppm H\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e2\u003c/sub\u003e) oxidative stress conditions and subsequently analyzed and compared to the control sample. Data are presented as mean ± standard deviation when multiple replicate measurements are performed. (A) \u003cem\u003eIn vitro\u003c/em\u003e protein expression analyzed by cell-based assay (n=3). (B) Quantitation of Met oxidation showing the distribution of key Met sites identified by LC-MS/MS (n=1). The asterisk indicates a residue in the unique N-terminal peptides of VP3. (C) Average hydrodynamic diameter (Z-Average) measured by DLS (n=5, technical replicates). (D) Monomeric capsid recovery analyzed by SE-UPLC (n=1). (E) Vector genome titer determined by ddPCR and normalized to the vg titer of the control (n=4, technical replicates). (F) Free DNA measured by fluorescence-based dye binding assay and normalized to the total genomic DNA amount (n=4, technical replicates). (G) Determination of VP ratio by microfluidic electrophoresis under 1000 ppm H₂O₂ oxidative stress (n=2, technical replicates).\u003c/p\u003e","description":"","filename":"Figure1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7596388/v1/d0142b72e70afd6187157ee5.jpg"},{"id":93165327,"identity":"69eb21b4-cd92-47a8-ad9d-011a07372283","added_by":"auto","created_at":"2025-10-09 17:48:45","extension":"jpg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":2682773,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eStability Changes of AAV8 Under pH Stress.\u003c/strong\u003e AAV8 samples were dialyzed into a glycine-based buffer at pH 3.0 and a Bis-Tris Propane based buffer at pH 9.0, respectively. The samples were subsequently analyzed and compared to a control sample at pH 7.3. (A) \u003cem\u003eIn vitro\u003c/em\u003eprotein expression (n=3). Quantitation of (B) Asn deamidation and (C) Asp isomerization (n=1). (D) Average hydrodynamic diameter (n=5, technical replicates). (E) Monomeric capsid recovery (n=1). (F) Normalized vector genome titer (n=4, technical replicates). (G) Normalized free DNA (n=4, technical replicates). (H) VP ratio (n=2, technical replicates).\u003c/p\u003e","description":"","filename":"Figure2.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7596388/v1/a194635dabb50c925e3939a2.jpg"},{"id":93165328,"identity":"db42aaa6-1bf6-4761-bfe1-596d7e888ba9","added_by":"auto","created_at":"2025-10-09 17:48:45","extension":"jpg","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":3207117,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eStability Changes of AAV8 Under Thermal Stress at 40°C and 45°C.\u003c/strong\u003e (A) Determination of T\u003csub\u003eonset \u003c/sub\u003eand T\u003csub\u003em\u003c/sub\u003e by DSF using SYBR\u003csup\u003e®\u003c/sup\u003e gold dye. (B) \u003cem\u003eIn vitro\u003c/em\u003e protein expression (n=3). Quantitation of (C) Asp isomerization, (D) Asn deamidation, and (E) Met oxidation (n=1). (F) Average hydrodynamic diameter (n=5, technical replicates). (G) Monomeric capsid recovery (n=1). (H) Normalized vector genome titer (n=4, technical replicates). (I) Normalized free DNA (n=4, technical replicates). (J) VP ratio (n=2, technical replicates).\u003c/p\u003e","description":"","filename":"Figure3.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7596388/v1/62c18b65d0c5dbccd3dcb614.jpg"},{"id":93164711,"identity":"cb685f7a-5d5d-46fc-9b12-cb2ebad16fe4","added_by":"auto","created_at":"2025-10-09 17:40:45","extension":"jpg","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":2173711,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eStability Changes of AAV8 Under Freeze-Thaw and Agitation Stress\u003c/strong\u003e. (A) \u003cem\u003eIn vitro\u003c/em\u003e protein expression (n=3). (B) Average hydrodynamic diameter (n=5, technical replicates). (C) Recovery of monomeric AAV8 measured by SE-UPLC (n=1). (D) Normalized vector genome titer (n=4, technical replicates). (E) The VP ratios remained unchanged after freeze-thaw cycles and agitation stress (n=2, technical replicates).\u003c/p\u003e","description":"","filename":"Figure4.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7596388/v1/a7408dbf0a2a25ecd5040eec.jpg"},{"id":93165984,"identity":"9e9a6009-2f4b-46b9-a5c4-73fd853842a0","added_by":"auto","created_at":"2025-10-09 17:56:45","extension":"jpg","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":2952620,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eAAV8 Capsid Structure.\u003c/strong\u003e 3D model (PDB: 2QA0) of an intact AAV8 capsid highlighting the location of key sites with significantly elevated PTM levels. (A) M561 is located on the capsid surface near the three-fold protrusion axis. It is highlighted in yellow, and the solvent accessibility analysis indicates limited solvent exposure of M561. (B) D220, highlighted in red, is oriented towards the interior of the capsid, near the five-fold axis pore. (C) N263, highlighted in red, is positioned on the capsid surface and is susceptible to deamidation under various stress conditions.\u003c/p\u003e","description":"","filename":"Figure5.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7596388/v1/11ff3fe1050d860ccbb0e910.jpg"},{"id":102488422,"identity":"b1bc3731-c871-489c-867a-67204848dc18","added_by":"auto","created_at":"2026-02-12 08:12:26","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":7141086,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7596388/v1/cab11d70-a87b-480b-a234-8db49e08ce84.pdf"},{"id":93164706,"identity":"0cc4f0ae-6238-4d8b-91f1-8830107f893b","added_by":"auto","created_at":"2025-10-09 17:40:45","extension":"xlsx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":12297,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eSupplemental Table 1 \u003c/strong\u003ePTM profile of AAV8 under oxidative stress. The asterisk indicates a residue located in the unique N-terminal peptides of the VP3 protein.\u003c/p\u003e","description":"","filename":"SupplementalTable1.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-7596388/v1/ba2c491670119f7817de657e.xlsx"},{"id":93164710,"identity":"ba13cedb-4456-4ddb-a561-662f28f6c627","added_by":"auto","created_at":"2025-10-09 17:40:45","extension":"xlsx","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":12276,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eSupplemental Table 2 \u003c/strong\u003ePTM profile of AAV8 under pH stress. The asterisk indicates a residue located in the unique N-terminal peptides of the VP3 protein.\u003c/p\u003e","description":"","filename":"SupplementalTable2.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-7596388/v1/82b07ed7b521eec81d22da1f.xlsx"},{"id":93164709,"identity":"cfcbecbe-622a-444a-a3b7-f36eb157161f","added_by":"auto","created_at":"2025-10-09 17:40:45","extension":"xlsx","order_by":3,"title":"","display":"","copyAsset":false,"role":"supplement","size":12527,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eSupplemental Table 3 \u003c/strong\u003ePTM profile of AAV8 under thermal stress. The asterisk indicates a residue located in the unique N-terminal peptides of the VP3 protein.\u003c/p\u003e","description":"","filename":"SupplementalTable3.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-7596388/v1/2d3922445d3b3ad0f46a3011.xlsx"},{"id":93164715,"identity":"c9b1a7d0-6fc2-4a82-9d14-46e49499526f","added_by":"auto","created_at":"2025-10-09 17:40:45","extension":"jpg","order_by":4,"title":"","display":"","copyAsset":false,"role":"supplement","size":343046,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eSupplemental Figure 1\u003c/strong\u003e Impact of DNaseI digestion on vector genome titer recovery of AAV8 after thermal stress at 40°C (A) and 45°C (B).\u003c/p\u003e","description":"","filename":"SupplementalFigure1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7596388/v1/0370370a5e18ca2de380d735.jpg"},{"id":93164722,"identity":"06e52267-7e0f-4662-8765-5800e8727635","added_by":"auto","created_at":"2025-10-09 17:40:45","extension":"xlsx","order_by":5,"title":"","display":"","copyAsset":false,"role":"supplement","size":11583,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eTable 1 \u003c/strong\u003eSummary of stress conditions utilized in AAV8 forced degradation study\u003c/p\u003e","description":"","filename":"Table1.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-7596388/v1/d50894a3d8ea0a56a538fda9.xlsx"},{"id":93165333,"identity":"876f584f-da91-4209-91a7-6d3e5abb5af8","added_by":"auto","created_at":"2025-10-09 17:48:45","extension":"xlsx","order_by":6,"title":"","display":"","copyAsset":false,"role":"supplement","size":12007,"visible":true,"origin":"","legend":"","description":"","filename":"Table2.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-7596388/v1/c4c8c7242be3febfdfd84213.xlsx"}],"financialInterests":"There is \u003cb\u003eNO\u003c/b\u003e conflict of interest to disclose.","formattedTitle":"Comprehensive Forced Degradation Study Revealing Diverse Chemical and Physical Degradation Pathways of AAV8","fulltext":[{"header":"Introduction","content":"\u003cp\u003eRecombinant adeno-associated virus (AAV) has attracted considerable attention for i\u003cem\u003en vivo\u003c/em\u003e gene delivery owing to its distinctive attributes for establishing durable gene expression in various target tissues and demonstrated safety and efficacy as a leading gene delivery tool. In recent years, remarkable progress has been made in the clinical application of AAV gene therapy. To date, eight AAV-based gene therapy products have received regulatory approval, and over 300 clinical trials are currently underway (\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e). Gene therapy represents a groundbreaking approach to potentially curing previously untreatable genetic diseases. It also addresses unmet medical needs in chronic and prevalent human diseases by offering more tolerable treatment options. Clinical studies and the regulatory approval process for AAV gene therapies often utilize a fast-track or accelerated approach, in contrast to the traditional development lifecycle for biological drugs. This reduced timeline, combined with often limited AAV materials during development, can pose significant challenges to the Chemistry, Manufacturing, and Controls development of AAV products. Comprehensive studies to support the development of optimal drug substance and drug product manufacturing process, stable formulations, and robust analytics often fail to be carried out for AAV products, especially prior to First-in-human studies. To mitigate the risks associated with an accelerated development approach, acquiring a thorough understanding of the critical quality attributes (CQAs) along with the degradation pathways of AAV under the various stresses that may occur during manufacturing, transport, storage, and clinical handling is highly desirable. This is particularly important for AAV, given the complexity of its molecular structure. AAV is a non-enveloped virus containing an icosahedral capsid encapsulating a single-stranded DNA genome of 4.7 kb flanked by a 145 bp Inverted Terminal Repeat at each end. The capsid is assembled by 60 viral proteins (VP) with VP1, VP2, and VP3 at a molar ratio of 1:1:10. VP1 is the longest among the three VP proteins, extending 137 amino acids beyond VP2 (\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e). This additional segment, known as the VP1 unique (VP1u) region, exhibits phospholipase A2 activity and is implicated in nuclear localization (\u003cspan additionalcitationids=\"CR5\" citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e). VP3 is composed of conserved β-strands linked by surface exposed variable loops which are known to be critical in determining the tropism of distinct AAV serotypes (\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e). Furthermore, AAV capsids have unique structural features that are critical to their function. These include channels with pore-like openings at each five-fold axis, which are essential for genome packaging and the externalization of VP1u during endosomal trafficking (\u003cspan additionalcitationids=\"CR8\" citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e). Additionally, the capsids exhibit protrusions surrounding the three-fold axis that play a pivotal role in targeting cell surface (\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e). These structural elements have been proposed to play a crucial role in the mechanisms by which AAV interacts with cellular surfaces and delivers transgenes into the nuclei of target tissues or cells. Similar to protein-based therapeutics, instability of AAVs can be mediated by either chemical or physical degradation pathways, or the combination of both (\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e). The most commonly observed chemical degradation mechanisms include amino acid modifications such as deamidation, oxidation, and isomerization (\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e, \u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e). In contrast, physical degradation often arises from conformational, colloidal, and interfacial mechanisms resulting in denaturation, aggregation, surface adsorption, and associated product loss (\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e). One unique physical degradation pathway of AAV is vector genome DNA leakage which has been observed under various stress conditions such as freeze-thaw and elevated temperatures (\u003cspan additionalcitationids=\"CR15\" citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e). It is presumably caused by conformational changes of AAV capsids leading to potential widening of the pore structure at the five-fold axis on the AAV capsids where DNA extrusion may occur (\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e). AAVs are commonly stored under frozen conditions and may encounter many stress factors during drug substance and drug product manufacturing, transport, storage, and clinical handling (\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e, \u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e, \u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e). These stress factors may include pH extremes, temperature variations, oxidation, multiple freeze thaw cycles, and mechanical stress. In this study, we applied these different types of stress to AAV8 in an optimized formulation. The conditions selected for this study are more extreme than what are typically used during routine stability assessment. The goal of this study is to generate degradation products which help to determine the degradation pathways of AAV8 under each stress condition. The results from these studies will be valuable for determining the CQAs of AAV8, supporting the development of robust formulation and stability indicating assays, as well as contributing to the assessment of manufacturing comparability to ensure consistent manufacturing of safe and effective AAV products for clinical applications. In addition, these results will further help to ensure the success with regulatory submissions, especially as the regulatory framework for gene therapies continues to evolve significantly.\u003c/p\u003e"},{"header":"Materials and Methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e\u003ch2\u003eMaterials\u003c/h2\u003e\u003cp\u003eAAV8 encoding a therapeutic transgene was produced using triple transfection approach in HEK293 cells by Virus Production Core at Regeneron Pharmaceuticals, Inc. (Tarrytown, NY, United States). All other excipients and reagents are reagent or compendial grades.\u003c/p\u003e\u003c/div\u003e\n\u003ch3\u003eStress Conditions\u003c/h3\u003e\n\u003cp\u003eAAV8 material was formulated with a base formulation buffer or dialyzed into the buffer of interest to achieve a target concentration of 2.0E\u0026thinsp;+\u0026thinsp;13 vg/mL. The base formulation includes a buffering agent to maintain a neutral pH and other excipients to maintain AAV8 stability. Buffer exchange was performed using Slide-A-Lyzer dialysis cassettes with a 10 kDa molecular weight cutoff (Thermo Fisher, Waltham, MA). After formulation or dialysis, the AAV8 was filled into cyclic olefin polymer vials (West Pharmaceutical, Exton, PA). To evaluate the impact of oxidative stress on AAV8, the samples were exposed to hydrogen peroxide (H\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e2\u003c/sub\u003e) concentrations of 1 ppm and 1000 ppm, respectively, followed by incubation at 25\u0026deg;C for 1 week. Untreated virus incubated under the same 25\u0026deg;C condition was used as a control. Upon completion of the incubation, the samples were dialyzed into the base formulation using the 10 kDa molecular weight cutoff Slide-A-Lyzer dialysis cassettes to remove residual H\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e2\u003c/sub\u003e. For the pH stress study, AAV8 was dialyzed into two different buffers at pH 3.0 (Glycine based buffer) and pH 9.0 (Bis-Tris Propane based buffer). Following dialysis, the samples were incubated at 25\u0026deg;C for 1 day and 1 week. To assess the effect of temperature on AAV8 stability, AAV8 was stored at 40\u0026deg;C and 45\u0026deg;C for 1, 2, and 4 weeks. The stability of AAV8 under freeze-thaw stress was assessed by subjecting the samples to 2 or 4 freeze-thaw cycles between \u0026minus;\u0026thinsp;80\u0026deg;C and room temperature. For the agitation stress study, the samples were vortexed at 1000 rpm for 60 minutes or 120 minutes on a benchtop vortexer.\u003c/p\u003e\u003cp\u003e\u003cb\u003eIn Vitro\u003c/b\u003e \u003cb\u003eProtein Expression Assay\u003c/b\u003e\u003c/p\u003e\u003cp\u003eThe \u003cem\u003ein vitro\u003c/em\u003e protein expression assay utilized a proprietary engineered cell line to analyze the expression level of the protein encoded by the transgene encapsidated in AAV8. These cells were seeded and incubated with AAV8, along with a proprietary gene editing reagent. After transduction, the protein of interest was analyzed using an in-house ELISA-based method. The signal versus log dilution was evaluated using non-linear regression analysis with GraphPad Prism 10.1 (Dotmatics, Boston, MA). All critical reagents used in the assay are protected under proprietary rights.\u003c/p\u003e\n\u003ch3\u003ePost-translational Modification (PTM) Analysis by liquid chromatography mass spectrometry (LC-MS/MS)\u003c/h3\u003e\n\u003cp\u003eThe AAV samples under different stress conditions were prepared for PTM analysis by LC-MS/MS based on the previously developed method with minor modifications (\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e). Briefly, a total of approximately 7 \u0026micro;g of AAV capsids from each sample was digested with a trypsin/rLys-C mixture (1:1 w/w ratio) at an enzyme-to-substrate ratio of 1:5 (w/w) at 37\u0026deg;C for 2 hours after denaturation, reduction, and alkylation. After digestion, 3 \u0026micro;L of 10% formic acid was added to quench the digestion. The digests were transferred to sample vials, and approximately 2.7 \u0026micro;g of the digests were injected for LC-MS/MS analysis.\u003c/p\u003e\u003cp\u003eAll the AAV8 samples were analyzed on an Orbitrap Exploris 480 mass spectrometer system coupled with a Vanquish Flex UPLC (Thermo Fisher). The digested peptides were separated on an ACQUITY Premier Peptide CSH C18 column (130 \u0026Aring;, 1.7 \u0026micro;m, 2.1 mm \u0026times; 150 mm, Waters) at a flow rate of 0.25 mL/min using a 75-minute gradient from 0.1% to 32% mobile phase B, then increasing to 45% buffer mobile phase B in 15 minutes. Mobile phase A and B were 0.1% (v/v) formic acid in water and 0.1% (v/v) formic acid in acetonitrile, respectively. The column temperature was set at 40\u0026deg;C. The mass spectrometer was set up with a 3.5 kV source voltage, a capillary temperature of 320\u0026deg;C, a sheath gas flow of 35, an auxiliary gas flow of 10, and an S-lens RF level of 50. MS1 data was collected in the range of 300 to 2000 m/z with a resolution of 120 K. The top 15 peptides were selected for MS/MS analysis at an HCD normalized collision energy of 30% and a resolution of 15 K.\u003c/p\u003e\u003cp\u003eAll the raw data were searched with Byonic software Version 5.8.6 (Protein Metrics, Cupertino, CA). Skyline software (MacCoss Lab Software, Seattle, WA) was used for PTM quantification by importing the search data from Byonic. To align the modification locations in the different VP proteins, all the modification sites were mapped to the VP1 sequence unless otherwise noted.\u003c/p\u003e\n\u003ch3\u003eParticle Size Distribution by Dynamic Light Scattering (DLS)\u003c/h3\u003e\n\u003cp\u003eParticle size distribution was assessed using a Zetasizer Ultra DLS instrument (Malvern, Westborough, MA) with a low-volume quartz cuvette (Malvern). Measurements were taken at a 90\u0026deg; angle, with each sample subjected to five replicate scans, each comprising 10 acquisitions of 10 seconds. Data was collected and analyzed with ZSXplorer software (Malvern).\u003c/p\u003e\n\u003ch3\u003eVector Genome Titer by Droplet Digital Polymerase Chain Reaction (ddPCR)\u003c/h3\u003e\n\u003cp\u003eThe AAV8 samples were subjected to treatment with DNase I (Thermo Fisher) to eliminate un-encapsulated DNA, followed by digestion of the AAV8 capsids using proteinase K (Thermo Fisher). The digested samples were then diluted with dilution buffer (20 mM Tris, 0.05% (v/v) Pluronic F-68, 0.002 \u0026micro;g/\u0026micro;L sheared salmon sperm DNA, pH 8.0) to achieve a target concentration range of 200 to 8,000 copies/\u0026micro;L, combined with ddPCR master mix (Bio-Rad, Hercules, CA) and transgene specific primer probe set, and partitioned on a AutoDG droplet generator (Bio-Rad). Polymerase Chain Reaction amplification was subsequently performed using a thermocycler (Bio-Rad), and the resulting droplets were analyzed with QxManager Software on a QX-200 droplet reader (Bio-Rad) to quantify the vector genome titer.\u003c/p\u003e\u003cdiv id=\"Sec8\" class=\"Section2\"\u003e\u003ch2\u003eCapsid Recovery Analysis by Size-Exclusion Chromatography (SEC)\u003c/h2\u003e\u003cp\u003eCapsid recovery was assessed using SEC on an ACQUITY UPLC H-Class system equipped with PDA and FLR detectors (Waters, Milford, MA) (\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e). The analysis employed a Sepax SRT SEC-1000 Column (Sepax, Newark, DE). Analyte separation was carried out using isocratic elution at a flow rate of 0.35 mL/min with a total runtime of 40 minutes. The mobile phase consists of 20 mM sodium phosphate, 300 mM sodium chloride, and 0.02% (w/v) poloxamer 188 at a pH of 7.3. Empower software (Waters) was used for peak integration and identification.\u003c/p\u003e\u003c/div\u003e\n\u003ch3\u003eFree DNA Analysis by Fluorescence-Based Dye Binding Assay\u003c/h3\u003e\n\u003cp\u003eFree DNA analysis was performed using the Qubit\u0026trade; ssDNA Assay Kit (Thermo Fisher). Stressed AAV8 samples were diluted in AAV8 formulation buffer and mixed with the Qubit\u0026trade; solution. Standards and test articles were loaded into a black 96-well microplate (Greiner Bio-One, Monroe, NC) and fluorescence was measured at 500 nm excitation and 525 nm emission using a Synergy Neo2 reader (Agilent, Santa Clara, CA). The percentage of free DNA was calculated by comparing to the free DNA level in a positive control AAV8 sample incubated at 75\u0026deg;C for 40 minutes.\u003c/p\u003e\n\u003ch3\u003eDetermination of Onset Temperature for Genome DNA Release (T) by Differential Scanning Fluorimetry (DSF)\u003c/h3\u003e\n\u003cp\u003eT\u003csub\u003eonset\u003c/sub\u003e of untreated AAV8 sample was determined using DSF on an Uncle system (Unchained Labs, Pleasanton, CA). SYBR\u0026reg; Gold Nucleic Acid Gel Stain (Thermo Fisher) was diluted to the appropriate concentration using AAV8 formulation buffer and then combined with the AAV8 sample. A total of 9 \u0026micro;L of the prepared mixture was loaded into the Unis (Unchained Labs) for melting temperature (T\u003csub\u003em\u003c/sub\u003e) analysis using a thermal ramp from 20\u0026deg;C to 95\u0026deg;C with a heating rate of 0.5\u0026deg;C per minute and a hold time of 60 seconds at each temperature step. SYBR\u0026reg; Gold was excited using a 473 nm laser. T\u003csub\u003eonset\u003c/sub\u003e value of AAV8 was determined based on the fluorescence intensity area between 500 nm and 650 nm across the temperature range using the Uncle software (Unchained Labs).\u003c/p\u003e\u003cdiv id=\"Sec11\" class=\"Section2\"\u003e\u003ch2\u003eVP Ratio Analysis by Microfluidic Electrophoresis\u003c/h2\u003e\u003cp\u003eThe VP ratio of AAV8 samples was analyzed using microfluidic electrophoresis on a LabChip\u0026reg; GXII Touch\u0026trade; HT protein characterization system (Revvity, Waltham, MA) with the HT Protein Express LabChip (Revvity) and Pico Protein Express assay reagent kit (Revvity). Samples were diluted to 1.0E\u0026thinsp;+\u0026thinsp;13 cp/mL in phosphate-buffered saline (Corning, NY, United States). Then, a total of 10 \u0026micro;L of reducing sample buffer (60 mM phosphate, 1.2% (w/v) lithium dodecyl sulfate, 80 mM dithiothreitol, pH 8.0) was added to 40 \u0026micro;L of the diluted sample. Following a 10-minute denaturation at 75\u0026deg;C, 5 \u0026micro;L of 16 \u0026micro;M dye was added to 5 \u0026micro;L of the sample mixture, incubated at 35\u0026deg;C for 15 minutes, then further diluted with 105 \u0026micro;L dilution solution provided in the kit. The LabChip was prepared according to the manufacturer's instructions. Data processing was performed using Empower software (Waters), and the calculation was conducted by integrating the signal from three major peak species observed in the electropherogram. To determine the VP ratio, the corrected peak area for each VP was divided by the total number of lysine residues in the respective VP, and the resulting values were used to calculate the VP ratio.\u003c/p\u003e\u003c/div\u003e"},{"header":"Results","content":"\u003cp\u003eThe manufacturing of AAV involves a complex series of processes that can expose the virus to various stress factors such as oxidation, acidic and basic pH conditions, high and low temperatures, freeze-thaw and agitation. To identify potential degradation pathways, AAV8 was subjected to relevant stress conditions as described in \u003cb\u003eTable\u0026nbsp;1\u003c/b\u003e. Under each stress condition, the impact on the biological activity of AAV8 was first assessed using an \u003cem\u003ein vitro\u003c/em\u003e transgene expression assay. Subsequently, potential degradation pathways were examined by measuring changes in several key AAV attributes. Potential chemical degradation, indicated by the formation of various PTM, was studied using an extensive LC-MS-based reduced peptide mapping method. Meanwhile, potential physical degradation pathways such as capsid aggregation, genome DNA release, capsid fragmentation, and associated titer loss were evaluated using various techniques. Specifically, capsid aggregation was probed by measuring the particle size distribution with DLS and the recovery of monomeric AAV using SEC. Genome DNA release was studied through a fluorescence-based DNA dye binding assay. Potential capsid fragmentation was evaluated using a microfluidic electrophoresis method. Finally, changes in vector genome titer were analyzed via ddPCR.\u003c/p\u003e\u003cdiv id=\"Sec13\" class=\"Section2\"\u003e\u003ch2\u003eStability Changes of AAV8 Under Oxidative Stress\u003c/h2\u003e\u003cp\u003eDuring biopharmaceutical drug product manufacturing process, vaporized hydrogen peroxide is commonly used to decontaminate isolators prior to aseptic filling. As a result, AAV products may be exposed to oxidative stress at about 1 ppm H\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e2\u003c/sub\u003e from the residual vaporized hydrogen peroxide during manufacturing (\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e). In this study, AAV8 at a concentration of 2E\u0026thinsp;+\u0026thinsp;13 vg/mL were subjected to oxidative stress by incubation with 1 ppm and 1000 ppm H\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e2\u003c/sub\u003e for one week at room temperature. Following the oxidative exposure, we found that under the highest oxidative stress condition (1000 ppm H\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e2\u003c/sub\u003e) assessed, a substantial reduction in AAV8 transgene expression was observed (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eA). In contrast, transgene expression remained stable under mild oxidative condition (1 ppm H\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e2\u003c/sub\u003e) when compared to control. Oxidation induced by exposure to hydrogen peroxide is known to affect the stability and biological activity of therapeutic proteins (\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e) by altering the protein primary structure through chemical modification of amino acid side chains. To characterize the changes which may be responsible for the reduced transgene expression under oxidative stress conditions, LC-MS-based reduced peptide mapping analysis was performed to achieve site-specific PTM quantitation. As depicted in Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eB, treatment with 1000 ppm H₂O₂ resulted in over 90% oxidation at several methionine residues, including M204, M212, and M561. M204 is part of the extended sequences of VP1 and VP2, while M212 is in the N-terminal region of VP3. M561 is shared by all three capsid proteins, positioned on the surface of the three-fold protrusion, and exhibits limited solvent accessibility (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e5\u003c/span\u003eA). Additionally, elevated methionine oxidation was observed at M374 (from 1.5% to 26%), M405 (from 0.2% to 13%), and M637 (from 0.4% to 16%) (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eB and \u003cb\u003eSupplemental Table\u0026nbsp;1\u003c/b\u003e). These residues are either minimally solvent-accessible or buried within the native capsid structure (23) consistent with their relatively low oxidation levels under strong oxidative stress conditions. Mild oxidative stress (i.e., 1 ppm H\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e2\u003c/sub\u003e) induced similar changes in methionine oxidation, although to a much lesser extent (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eB). As the transgene expression remained stable under mild oxidative stress compared to the control, it was concluded that moderate oxidation (M204 from 1.3% to 10.1% and M212 from 1.3% to 8.9%) of these methionine residues (\u003cb\u003eSupplemental Table\u0026nbsp;1\u003c/b\u003e) did not significantly impact AAV biological activity. Finally, no significant changes in other PTM, including asparagine deamidation, aspartic acid isomerization, VP protein N-terminal acetylation, and serine/threonine phosphorylation, were observed under either strong or mild oxidative stress conditions (data not shown). Previous studies have reported that oxidative modifications in therapeutic proteins often lead to alteration in higher-order structures, promote aggregate formation, and generate products with potentially reduced biological activity (\u003cspan additionalcitationids=\"CR25\" citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e). To understand whether physical degradation occurred alongside chemical modifications in the AAV8 samples under oxidative stress and contributed to the observed reduction in transgene expression various analytical techniques as described above were utilized. Despite the particle size remained consistent under strong oxidative stress conditions (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eC), SEC analysis revealed up to approximately 10% loss in monomeric AAV8 recovery, indicating that capsid titer loss may be attributed to the surface adsorption of denatured AAV8 products onto the container-closure system (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eD). Meanwhile, the increasing levels of oxidative stress were associated with a trend of decreasing vector genome titer, with up to ~\u0026thinsp;15% reduction observed under 1000 ppm H₂O₂ treatment (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eE). This decline was accompanied by a corresponding increase in free DNA levels, rising from ~\u0026thinsp;0.3% to 1.8% (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eF). These observations may be attributed to conformational instability of AAV8 capsid under oxidative stress, potentially driven by oxidation-induced conformational changes in structure, which in turn leads to the release of genomic DNA. The methionine oxidation profile further reveals capsid structural changes under oxidative stress, as maximum oxidation of M204 and M212 coincides with extensive oxidation of other methionine residues, including nearly complete oxidation of M561. Importantly, M561 is largely inaccessible to solvent in the native state (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e5\u003c/span\u003eA), suggesting that additional structural rearrangements are necessary for it to become susceptible to oxidation. Interestingly, a prior study identified the critical role of M203 and M211 in capsid assembly. Point mutation of these two methionine residues to Leu led to failed capsid production. Therefore, it is reasonable to hypothesize that the near-complete oxidation of these two methionine residues under strong oxidative stress conditions may significantly destabilize the capsid structure, thereby facilitating the DNA release (\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e). The stoichiometry of viral proteins was also analyzed, revealing that both the control and 1 ppm H₂O₂ treated samples exhibited a VP1:VP2:VP3 ratio of approximately 1:1.7:10.4 \u003cb\u003e(\u003c/b\u003eFig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eG), consistent with the commonly reported VP molar ratio of approximately 1:1:10 for AAVs demonstrating good transduction efficiency (\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e, \u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e). However, exposure of AAV8 to 1000 ppm H₂O₂ resulted in a noticeable change in viral protein stoichiometry, with the VP3 ratio increasing from 10.4 to 12.2 (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eG). This suggests fragmentation of capsids may occur under strong oxidative stress conditions, resulting in increased VP3 ratio. The data collectively suggests both chemical and physical degradation pathways occur under oxidative stress. Alterations in the transgene expression of AAV8 are likely to be attributed to the combination effect from methionine oxidation on capsid proteins, genomic DNA leakage caused by oxidation-induced capsid conformational change and instability, reduction of capsid titer due to associated surface adsorption, as well as increased VP3 ratio as a result of fragmentation of capsid under strong oxidative stress.\u003c/p\u003e\u003cp\u003e\u003c/p\u003e\u003cp\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec14\" class=\"Section2\"\u003e\u003ch2\u003eStability Changes of AAV8 Under pH Stress\u003c/h2\u003e\u003cp\u003eThe pH-dependent degradation behavior of AAV8 was evaluated under extreme acidic and basic conditions to simulate potential exposures during the drug substance manufacturing process. Specifically, AAV8 was dialyzed into respective buffers at pH 3.0 and pH 9.0, followed by incubation at 25\u0026deg;C for up to seven days. A buffer at neutral pH (7.3) was used as a control. Consistent with prior findings that AAV8 and AAV9 lose transduction efficiency under highly acidic conditions (\u003cspan additionalcitationids=\"CR31\" citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e), our results revealed a substantial reduction in transgene expression in AAV8 following seven days of incubation at pH 3.0 (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e2\u003c/span\u003eA). In contrast, transgene expression levels in the AAV8 samples incubated at pH 9.0 remained comparable to those observed in the control buffer at pH 7.3 (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e2\u003c/span\u003eA). A comprehensive PTM analysis revealed that AAV8 exhibited increased asparagine deamidation at pH 9.0, with levels at N57, N94, and N263 reaching approximately 38%,5%, and 29%, respectively (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e2\u003c/span\u003eB). Notably, N57 and N94 are located at VP1u region, whereas N263 is surface-exposed (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e5\u003c/span\u003eC) and situated in the region shared by all three capsid proteins. Although these asparagine deamidations were found to be critical for AAV8 transduction efficiency in a previous report using point mutation analysis (\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e), our results showed that moderate increases in deamidation at N57, N94 and N263, induced by pH 9.0 stress, did not significantly affect AAV8 transgene expression. This discrepancy is likely due to differences in deamidation levels: point mutations result in 100% change, whereas real-life stress typically induces only moderate levels. Therefore, AAV capsids may exhibit greater tolerance to deamidation than previously understood, or the impact of deamidation might vary based on the specific residues involved within the capsid structure. Furthermore, isomerization analysis revealed minor changes under acidic condition at D4, D220, and D628, with increases from approximately 3% to 9%, 5% to 7%, and 2.5% to 3.1%, respectively (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e2\u003c/span\u003eC). The increased isomerization observed under pH 3.0 stress, compared to neutral pH and pH 9.0, aligns with the mechanism of this modification, as slightly acidic conditions facilitate the formation of succinimide, the intermediate product in Asp isomerization. No other notable PTM changes were detected under pH 9.0 and 3.0 conditions. These findings indicate that, although extreme pH conditions can induce chemical modifications in AAV capsid proteins, such modifications generally occur at low levels at room temperature over reasonably short durations (e.g., up to 7 days).\u003c/p\u003e\u003cp\u003e\u003c/p\u003e\u003cp\u003eSubsequently, we investigated whether physical degradation of AAV8 contributes to the observed reduction in AAV8 transgene expression under pH 3.0 stress condition. We observed that, at pH 3.0, the particle size of AAV8 increased from approximately 25 nm to 44 nm immediately after dialysis and further expanded to approximately 65 nm after 7 days of incubation at pH 3.0, indicating the formation of large AAV8 aggregates (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e2\u003c/span\u003eD). In contrast, the particle size of AAV8 remained stable at pH 9.0 or 7.3 throughout the 7-day incubation period. Interestingly, SEC analysis revealed negligible changes in monomeric AAV recovery under both pH 3.0 and pH 9.0 conditions (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e2\u003c/span\u003eE). This suggests the large aggregates detected at pH 3.0 by DLS may be reversible under the running condition of SEC. Thus, the stability-indicating capability of SEC for detecting and quantifying AAV aggregates remains to be further evaluated. Additionally, a slight reduction in vector genome titer was observed under both pH 3.0 and pH 9.0 conditions, with decreases of 13% and 9%, respectively (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e2\u003c/span\u003eF). Free DNA levels in the AAV8 sample increased from 0.4% to 1.3% immediately after dialysis into the pH 3.0 buffer, with no further increase observed after the 7-day incubation at pH 3.0 (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e2\u003c/span\u003eG). Similar genomic DNA leakage from viral particles at pH 4.0 has been reported for AAV2 and AAVv66 (\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e). Viral protein stoichiometry analysis revealed that the VP3 ratio increased from 10.5 to 11.4 at pH 9.0 and to 11.9 at pH 3.0, while the VP2 ratio decreased from 1.7 to 1.5 and 1.3, respectively (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e2\u003c/span\u003eH). This suggests high pH up to 9.0 and low pH near 3.0 may induce capsid fragmentation. Exposure of AAVs to these extreme pH conditions during the manufacturing process should be carefully controlled or minimized when possible. In summary, our findings indicate that during the drug substance manufacturing process, AAV8 may maintain acceptable stability and quality under strong basic conditions but is susceptible to degradation under strong acidic conditions. The degradations likely involve both chemical and physical pathways, with aggregation being the major contributor to the loss of AAV8 biological activity in strong acidic environments.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec15\" class=\"Section2\"\u003e\u003ch2\u003eStability Changes of AAV8 Under 40\u0026deg;C and 45\u0026deg;C\u003c/h2\u003e\u003cp\u003eThe impact of thermal stress on AAV8 was assessed by exposing AAV8 to elevated temperatures for durations of up to four weeks. The onset temperature for vector genome DNA release (T\u003csub\u003eonset\u003c/sub\u003e) of AAV8 in the optimized AAV8 formulation, determined using DSF, was approximately 50\u0026deg;C (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e3\u003c/span\u003eA), and was used to guide the selection of stress temperatures. To ensure sufficient generation of degradation products and to understand the differential effect of temperature on AAV8, two stress temperatures of 40\u0026deg;C and 45\u0026deg;C were assessed in this study following the general rule of thumb that the selected thermal stress temperature should stay below T\u003csub\u003eonset\u003c/sub\u003e and at least 10\u0026deg;C to 20\u0026deg;C below T\u003csub\u003em\u003c/sub\u003e (\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e). As illustrated in Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e3\u003c/span\u003eB, subjecting AAV8 to up to 4 weeks of incubation at 40\u0026deg;C and 45\u0026deg;C resulted in a drastic decrease in transgene expression, demonstrating a temperature-dependent effect on impacting AAV stability. After 4 weeks, the transgene expression in the AAV8 sample was greatly reduced at 40\u0026deg;C and completely abolished at 45\u0026deg;C. High temperature incubation also led to extensive chemical modifications on AAV8 capsid proteins. After incubating AAV8 at 40\u0026deg;C and 45\u0026deg;C for 4 weeks, increased aspartic acid isomerization was detected at D4 (from 3% to 24% and 43%), D69 (from 0.3% to 4% and 11%), and D220 (from 5% to 19% and 27%) (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e3\u003c/span\u003eC). Elevated asparagine deamidation was observed at N57 (from 18% to 50% and 82%), N94 (from 2% to 21% and 56%), and N263 (from 14% to 35% and 53%) (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e3\u003c/span\u003eD). Additionally, methionine oxidation increased notably at M204 (from ~\u0026thinsp;8% to 15%), M212 (from ~\u0026thinsp;9% to 17%), and M212* (from ~\u0026thinsp;5% to 12%) (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e3\u003c/span\u003eE). Consistent with previous findings, the VP1u, VP1/2, and VP3 N-terminus regions were identified as hotspots for PTM formation under thermal stress (\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e). The VP1u externalization under heat shock, along with its unstructured conformation, may provide a plausible explanation for the accelerated deamidation at N57 and N94 and isomerization at D4 and D69 (\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e). Additionally, a recent hydrogen/deuterium exchange mass spectrometry study analyzed AAV8 incubated at 60\u0026deg;C and revealed increased deuterium uptake in the five-fold axis region, specifically in a polypeptide sequence spanning residues A205 to W229 (\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e). The increased structure dynamics of this region under thermal stress correlated with the accelerated formation of oxidation at M204 and M212, as well as isomerization at D220 (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e5\u003c/span\u003eB). Finally, the extended levels of deamidation at N263 under thermal stress are attributed to its high solvent accessibility and favorable Asn-Gly motif, consistent with previous reports (\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e). Moreover, our results showed that the rate of PTM formation in AAV8 accelerates at 45\u0026deg;C compared to 40\u0026deg;C, correlating with reduced transgene expression at 45\u0026deg;C. Interestingly, prior studies conducted under 1 ppm H\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e2\u003c/sub\u003e oxidative stress and pH 9.0 stress revealed that moderate levels of Met oxidation and Asn deamidation did not significantly affect biological activity of AAV8, indicating that other degradation pathways may also play a role.\u003c/p\u003e\u003cp\u003e\u003c/p\u003e\u003cp\u003eIt is well known that therapeutic proteins are prone to extended exposure at high temperatures, which may induce conformational changes resulting in physical instability and/or reduced biological activity (\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e). Aligning with previous reports (\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e, \u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e), our results showed that the particle size of AAV8, as measured by DLS, increased from 26 nm to 31 nm and 62 nm after 4 weeks at 40\u0026deg;C and 45\u0026deg;C, respectively (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e3\u003c/span\u003eF). This was accompanied by a significant loss in monomeric AAV recovery, as revealed by SEC analysis, which showed reductions of ~\u0026thinsp;75% and 26% after the 4-week incubation at 40\u0026deg;C and 45\u0026deg;C, respectively (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e3\u003c/span\u003eG). These results indicate, unlike the AAV aggregates formed under pH 3.0 condition, the large AAV aggregates formed after extended exposure at high temperatures might be due to profound and extensive conformational changes. It is likely these aggregates remain irreversible under the SEC running conditions and thus cannot enter the SEC column. Concurrently, a significant reduction in vector genome titer (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e3\u003c/span\u003eH) and an increase in free DNA (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e3\u003c/span\u003eI) were also observed, especially at 45\u0026deg;C. To assess the impact of vector genome DNA release on genome titer loss, genome titers of the AAV8 samples stressed at 40\u0026deg;C and 45\u0026deg;C were also measured without DNase I digestion prior to capsid denaturation. We found omitting DNase I digestion improved genome titer recovery from 40% to 75% for AAV8 incubated at 45\u0026deg;C for 4 weeks (\u003cb\u003eSupplemental Fig.\u0026nbsp;1A and 1B\u003c/b\u003e) supporting the presence of externalized DNA. Free DNA-mediated capsid aggregation, along with the subsequent sample loss due to either precipitation or surface adsorption, likely accounts for the remaining genome titer loss. In addition, thermal stress resulted in substantial alterations in viral protein ratios. The VP3 ratio increased from 10.3 to 12.1 at 40\u0026deg;C and 16.3 at 45\u0026deg;C, while the VP2 ratio rose from 1.6 to 1.8 and 2.5, respectively (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e3\u003c/span\u003eJ). This suggests fragmentation of capsids occurs under these thermal stress conditions, especially at 45\u0026deg;C. Altogether, our study revealed that several physical degradation pathways of AAV8 including capsid aggregation, genome DNA release, viral protein fragmentation, and associated surface adsorption, are triggered by high-temperature stress. Additionally, we observed a significant difference in the extent of physical degradation at 40\u0026deg;C versus 45\u0026deg;C, indicating that AAV8 capsids might lose structural integrity at temperatures approaching the T\u003csub\u003eonset\u003c/sub\u003e temperature of 50\u0026deg;C in this formulation. It is clear a combination effect of both chemical and physical degradations of AAV8 accounts for the reduction of biological activity under thermal stress.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec16\" class=\"Section2\"\u003e\u003ch2\u003eStability Changes of AAV8 Under Freeze-Thaw and Agitation Stress\u003c/h2\u003e\u003cp\u003eAAV8 was subjected to two and four freeze-thaw cycles between \u0026minus;\u0026thinsp;80\u0026deg;C and room temperature, or vortexing at 1000 rpm for durations of 60 minutes and 120 minutes, to assess its degradation profile under freeze-thaw and agitation stress conditions. Our results showed that no meaningful changes to the AAV8 transgene expression, particle size distribution, vector genome titer, recovery of monomeric AAV8 capsids, and viral protein ratio were detected in the freeze-thaw or agitation stressed samples (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e4\u003c/span\u003eA to \u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e4\u003c/span\u003eE). These results indicate that neither chemical nor physical degradations of AAV8 occurred in the base formulation under the freeze-thaw and agitation stress conditions assessed in this study.\u003c/p\u003e\u003cp\u003e\u003c/p\u003e\u003c/div\u003e"},{"header":"Discussion","content":"\u003cp\u003eIn this work, we performed a comprehensive forced degradation study of AAV8 by applying various types of stresses which might be encountered during AAV manufacturing, storage, shipping and handling, but exceeding the conditions commonly used for stability assessment. Our goal is to gain an in-depth understanding of the major degradation pathways under each type of stress and recommend CQAs of AAV to monitor and control during manufacturing, product release, and stability testing. Performing such a study is particularly important in the case of AAV gene therapy drug development due to the complexity of their molecular structure and the limited prior knowledge about the potential influence of these stresses on the product attributes of various AAV serotypes. Although the degradation products generated from forced degradation studies may not be formed under relevant manufacturing, storage, and in-use conditions, the result of the study provides critical insight into developing stability-indicating assays, designing effective strategies for manufacturing, formulation, and drug product processes, as well as establishing the product degradation profiles for comparability assessment.\u003c/p\u003e\u003cp\u003eIn this study, we employed various analytical techniques capable of detecting and quantifying the different types of degradation products that may alter the sequence, structure, concentration, purity, or biological activity of the stressed AAV8 samples. Comprehensive and appropriate characterization of the biochemical, biophysical, and biological properties of these samples is an essential part for a well-designed forced degradation study for achieving a thorough understanding of the chemical and physical degradation mechanisms of the product. While LC-MS/MS was found sufficient for characterizing the site-specific chemical modifications in stressed AAV8 samples, the complexity of physical degradation mechanisms for AAVs and our evolving understanding of preliminary critical quality attributes necessitated the use of a large and diverse set of assays to monitor the stability-indicating preliminary critical quality attributes. These assays include vector genome titer by ddPCR, aggregation or particle size distribution by DLS, monomeric AAV capsid recovery by SEC, free DNA by dye-binding assay, viral protein ratio by microfluidic electrophoresis, and transgene protein expression by cell-based assay. Indeed, these assays allow us to form a much more complete picture of the degradation pathways of AAV8 which occur under the various modes of stress. Many of the degradation pathways identified in this study either failed to be revealed or analyzed to the same extent in detail in previously reported forced degradation studies of other AAV serotypes (\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e, \u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e, \u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e). Furthermore, our results showed the assays used in this study demonstrated sufficient sensitivity and good performance for detecting and quantifying the AAV8 degradation products and have great potential to be established in a quality control setting as stability-indicating release assays to support AAV product release and shelf-life stability testing.\u003c/p\u003e\u003cp\u003eBy exposing AAV8 to commonly used forced degradation conditions including oxidation, high and low pH, high temperature, freeze-thaw, and agitation stress, we have identified the major chemical degradation pathways of AAV8 are methionine oxidation, asparagine deamidation, and aspartic acid isomerization (\u003cb\u003eTable\u0026nbsp;2\u003c/b\u003e). The major physical degradation pathways of AAV8 include aggregation, genome DNA leakage, viral protein fragmentation, and associated surface adsorption potentially due to conformational changes in capsids and/or aggregation (\u003cb\u003eTable\u0026nbsp;2\u003c/b\u003e). Specifically, strong oxidative stress causes significant methionine oxidation on AAV8 capsid proteins. This likely induces conformational change in the capsids, which subsequently induces genome DNA leakage, fragmentation of viral proteins, and associated surface adsorption. As a result, a substantial reduction of AAV8 transgene expression was observed under strong oxidative stress. In contrast, chemical degradations are not the major degradation pathway for AAV8 under pH stress. We found that AAV8 maintains acceptable stability and quality in our previously developed formulation under strong basic conditions but is susceptible to physical degradation under strong acidic conditions. Extreme low pH causes formation of large AAV8 aggregates and accelerates viral protein fragmentation, which are likely to be the major degradation pathways underlying the loss of AAV8 transgene expression at pH 3.0. Our study also revealed that high temperature stress accelerates various chemical and physical degradation pathways. Exposure of AAV8 at 40°C and 45°C after 4 weeks led to significantly elevated aspartic acid isomerization and asparagine deamidation, as well as a notable increase in methionine oxidation. Extensive aggregation, viral protein fragmentation, and genome DNA leakage were also observed under high temperature stress. The combination effect from these changes caused drastic abolishment of AAV8 transgene expression in a temperature-dependent manner. In addition, we observed a surprisingly large difference in the extent of chemical and physical degradation at 40°C versus 45°C, indicating AAV8 capsids might lose structural integrity at temperatures approaching the T\u003csub\u003eonset\u003c/sub\u003e temperature of 50°C in this formulation. Under the freeze-thaw and agitation stress conditions evaluated in this study, minimal degradation of AAV8 such as aggregation or particulate formation was observed, indicating the formulation factors we selected for AAV8 including pH, ionic strength, composition and concentration of cryoprotection, and surfactant are sufficient to protect AAV8 against the interfacial stress and phase separation occurred under the conditions evaluated in this study, thus maintaining good stability.\u003c/p\u003e\u003cp\u003eIt is worthwhile to mention that the formulation conditions selected for forced degradation studies could influence the study results because pH, ionic strength, as well as the composition and concentration of each excipient in the formulation may impact chemical stability and/or physical stability of a protein, with the latter mainly attributed to influence on colloidal stability of the protein (\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e, \u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e). This protective effect may contribute to the mild changes observed in oxidation and transgene expression of AAV8 when exposed to 1 ppm H\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e2\u003c/sub\u003e, or it is possible that the degree of methionine oxidation did not reach the threshold required to compromise capsid stability. In addition, a standardized AAV manufacturing process has yet to be developed so far due to many practical challenges such as the complexity of the molecular structure of AAV, the fact that variations in AAV capsid structure and serotype may demand changes in the production and/or purification process, and most importantly, the intrinsic heterogenous nature of AAV rendering high-resolution separation of empty, partial, and full capsids extremely difficult especially during large-scale clinical manufacturing process. Consequently, AAVs from different resources not only vary in AAV serotypes or capsid structure, transgene sequence, format, or length, they could also have different levels of chemical modifications, purity, or impurity profiles. These differences may have an impact on the quality and/or stability of the AAV products. Given the absence of well-established standardized analytics for AAV characterization and definition of CQAs for AAV, caution should be taken when analyzing and interpreting results from different forced degradation studies reported in literature.\u003c/p\u003e\u003cp\u003eIn summary, our study has elucidated how AAV8 degrades under various stress conditions. These findings are likely applicable to other AAV serotypes as the capsid protein sequences and structure are highly conserved among certain serotypes. In addition, the knowledge gained from this study can accelerate analytical, formulation, and process development efforts, supporting the establishment of robust manufacturing process and the production of safe and efficacious AAV gene therapy products.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eData Availability Statement\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe data supporting the findings of this study are available from the corresponding author upon request.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEthical Approval\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNo animal studies were conducted in this study.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting Interests\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare no competing interests.\u003c/p\u003e\u003ch2\u003eFunding\u003c/h2\u003e\u003cp\u003eThe work presented in this manuscript was funded by Regeneron Pharmaceuticals, Inc. All authors are full-time employees and shareholders of Regeneron Pharmaceuticals, Inc.\u003c/p\u003e\u003ch2\u003eAuthor Contributions\u003c/h2\u003e\u003cp\u003eConceptualization: KYL, SN, SW, LZ, data acquisition and analysis: YCC, KYL, SN, TNT, ST, YH, YY, SM, HAR, AH, NL, MR, writing, review and editing: KYL, SN, LZ, SW, DL, NL, MS, supervision: DL, NL, MS.\u003c/p\u003e\u003ch2\u003eAcknowledgements\u003c/h2\u003e\u003cp\u003eThe authors acknowledge Zhe Zhang, Sheldon Mink, and Andrew Tustian at Viral Production Core for providing AAV8.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eWang J-H, Gessler DJ, Zhan W, Gallagher TL, Gao G. Adeno-associated virus as a delivery vector for gene therapy of human diseases. Signal Transduct Target therapy. 2024;9(1):78.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eSuarez-Amaran L, Song L, Tretiakova AP, Mikhail SA, Samulski RJ. AAV vector development, back to the future. Mol Ther. 2025;33(5):1903\u0026ndash;36.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eW\u0026ouml;rner TP, Bennett A, Habka S, Snijder J, Friese O, Powers T, et al. Adeno-associated virus capsid assembly is divergent and stochastic. Nat Commun. 2021;12(1):1642.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLarge EE, Silveria MA, Zane GM, Weerakoon O, Chapman MS. Adeno-associated virus (AAV) gene delivery: dissecting molecular interactions upon cell entry. Viruses. 2021;13(7):1336.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eGirod A, Wobus CE, Z\u0026aacute;dori Z, Ried M, Leike K, Tijssen P, et al. The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity. J Gen Virol. 2002;83(5):973\u0026ndash;8.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eAgbandje-McKenna M, Kleinschmidt J. AAV capsid structure and cell interactions. Adeno-associated virus: methods protocols. 2011:47\u0026ndash;92.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKronenberg S, B\u0026ouml;ttcher B, von der Lieth CW, Bleker S, Kleinschmidt JA. A conformational change in the adeno-associated virus type 2 capsid leads to the exposure of hidden VP1 N termini. J Virol. 2005;79(9):5296\u0026ndash;303.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eVenkatakrishnan B, Yarbrough J, Domsic J, Bennett A, Bothner B, Kozyreva OG, et al. Structure and dynamics of adeno-associated virus serotype 1 VP1-unique N-terminal domain and its role in capsid trafficking. J Virol. 2013;87(9):4974\u0026ndash;84.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eBleker S, Sonntag F, Kleinschmidt JA. Mutational analysis of narrow pores at the fivefold symmetry axes of adeno-associated virus type 2 capsids reveals a dual role in genome packaging and activation of phospholipase A2 activity. J Virol. 2005;79(4):2528\u0026ndash;40.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eRaupp C, Naumer M, M\u0026uuml;ller OJ, Gurda BL, Agbandje-McKenna M, Kleinschmidt JA. The threefold protrusions of adeno-associated virus type 8 are involved in cell surface targeting as well as postattachment processing. J Virol. 2012;86(17):9396\u0026ndash;408.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eGrossen P, Koukelli IS, van Haasteren J, Machado AH, D\u0026uuml;rr C. The ice age\u0026ndash;A review on formulation of Adeno-associated virus therapeutics. Eur J Pharm Biopharm. 2023;190:1\u0026ndash;23.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLiu H, Ponniah G, Zhang H-M, Nowak C, Neill A, Gonzalez-Lopez N, et al. editors. vitro and in vivo modifications of recombinant and human IgG antibodies. Taylor \u0026amp; Francis; 2014. MAbs.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eRodriguez A, Jalimarada-Shivakumar S, Banazadeh A, Afroz S, Ali A, Deng K, et al. Insight into the degradation pathways of an AAV9. J Pharm Sci. 2024;113(9):2967\u0026ndash;73.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eBee JS, O'Berry K, Zhang YZ, Phillippi MK, Kaushal A, DePaz RA, et al. Quantitation of trace levels of DNA released from disrupted adeno-associated virus gene therapy vectors. J Pharm Sci. 2021;110(9):3183\u0026ndash;7.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eXu Y, Jiang B, Samai P, Tank S-M, Shameem M, Liu D. Genome DNA leakage of adeno\u0026ndash;associated virus under freeze\u0026ndash;thaw stress. Int J Pharm. 2022;615:121464.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLi S, Wang X, Lai K-Y, Wert J, Zhi L, Shameem M et al. Development of an optimized SEC method for characterization of genome DNA leakage from adeno-associated virus products. Anal Bioanal Chem. 2024:1\u0026ndash;10.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eYe X, Hu M, Hu Y, Qiu H, Li N. HDX-MS reveals pH and temperature-responsive regions on AAV capsids and the structural basis for DNA release. Gene Ther. 2025:1\u0026ndash;11.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eManning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27:544\u0026ndash;75.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eSom M, Gikanga B, Kanapuram V, Yadav S. Drug product formulation and fill/finish manufacturing process considerations for AAV-based genomic medicines. J Pharm Sci. 2024.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eXing T, Li S, Tang S, Huang Y, Liu G, Yan Y, et al. Distinct chemical degradation pathways of AAV1 and AAV8 under thermal stress conditions revealed by analytical anion exchange chromatography and LC-MS-based peptide mapping. J Pharm Biomed Anal. 2024;251:116452.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eAli D, Pel\u0026aacute;ez SS, Lemazurier T, Schroeter A, Adler M, Bong J, et al. Vaporized Hydogen Peroxide Uptake by Tubing used for Aseptic Fill-Finish Manufacturing of Biopharmaceutical Drug Products. Eur J Pharm Biopharm. 2025;207:114618.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eHalley J, Chou YR, Cicchino C, Huang M, Sharma V, Tan NC, et al. An industry perspective on forced degradation studies of biopharmaceuticals: survey outcome and recommendations. J Pharm Sci. 2020;109(1):6\u0026ndash;21.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eNam H-J, Lane MD, Padron E, Gurda B, McKenna R, Kohlbrenner E, et al. Structure of adeno-associated virus serotype 8, a gene therapy vector. J Virol. 2007;81(22):12260\u0026ndash;71.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKerwin BA, Remmele RL Jr. Protect from light: photodegradation and protein biologics. J Pharm Sci. 2007;96(6):1468\u0026ndash;79.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLiu D, Ren D, Huang H, Dankberg J, Rosenfeld R, Cocco MJ, et al. Structure and stability changes of human IgG1 Fc as a consequence of methionine oxidation. Biochemistry. 2008;47(18):5088\u0026ndash;100.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eTorosantucci R, Sch\u0026ouml;neich C, Jiskoot W. Oxidation of therapeutic proteins and peptides: structural and biological consequences. Pharm Res. 2014;31:541\u0026ndash;53.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eWarrington KH Jr, Gorbatyuk OS, Harrison JK, Opie SR, Zolotukhin S, Muzyczka N. Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus. J Virol. 2004;78(12):6595\u0026ndash;609.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eMcColl-Carboni A, Dollive S, Laughlin S, Lushi R, MacArthur M, Zhou S, et al. Analytical characterization of full, intermediate, and empty AAV capsids. Gene Ther. 2024;31(5):285\u0026ndash;94.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eZhang Z, Park J, Barrett H, Dooley S, Davies C, Verhagen MF. Capillary electrophoresis-sodium dodecyl sulfate with laser-induced fluorescence detection as a highly sensitive and quality control-friendly method for monitoring adeno-associated virus capsid protein purity. Hum Gene Ther. 2021;32(11\u0026ndash;12):628\u0026ndash;37.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLowell JA, Mah KM, Bixby JL, Lemmon VP. AAV8 transduction capacity is reduced by prior exposure to endosome-like pH conditions. Neural regeneration Res. 2021;16(5):851\u0026ndash;5.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLengler J, Gavrila M, Brandis J, Palavra K, Dieringer F, Unterthurner S, et al. Crucial aspects for maintaining rAAV stability. Sci Rep. 2024;14(1):27685.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003ePotter M, Lins B, Mietzsch M, Heilbronn R, Van Vliet K, Chipman P et al. A simplified purification protocol for recombinant adeno-associated virus vectors. Mol Therapy Methods Clin Dev. 2014;1.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eGiles AR, Sims JJ, Turner KB, Govindasamy L, Alvira MR, Lock M, et al. Deamidation of amino acids on the surface of adeno-associated virus capsids leads to charge heterogeneity and altered vector function. Mol Ther. 2018;26(12):2848\u0026ndash;62.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eHsu H-L, Brown A, Loveland AB, Lotun A, Xu M, Luo L, et al. Structural characterization of a novel human adeno-associated virus capsid with neurotropic properties. Nat Commun. 2020;11(1):3279.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003evan Maarschalkerweerd A, Wolbink G-J, Stapel SO, Jiskoot W, Hawe A. Comparison of analytical methods to detect instability of etanercept during thermal stress testing. Eur J Pharm Biopharm. 2011;78(2):213\u0026ndash;21.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eYamaguchi Y, Shimojo S, Ikeda T, Fukuhara M, Tsunaka Y, Shibuya R, et al. Unfolding of viral protein 1 N-termini facilitates genome ejection from recombinant adeno-associated virus serotype 8. Molecular Therapy Methods \u0026amp; Clinical Development; 2025.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eNowak C, Cheung K, Dellatore JM, Katiyar S, Bhat A, Sun R J, et al. editors. Forced degradation of recombinant monoclonal antibodies: A practical guide. Taylor \u0026amp; Francis; 2017. MAbs.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eJarand CW, Baker K, Petroff M, Jin M, Reed WF. DNA released by adeno-associated virus strongly alters capsid aggregation kinetics in a physiological solution. Biomacromolecules. 2024;25(5):2890\u0026ndash;901.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKumar P, Wang M, Kumru OS, Hickey JM, Sanmiguel J, Zabaleta N, et al. Correlating physicochemical and biological properties to define critical quality attributes of a rAAV vaccine candidate. Mol Therapy Methods Clin Dev. 2023;30:103\u0026ndash;21.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eWang W, Nema S, Teagarden D. Protein aggregation\u0026mdash;Pathways and influencing factors. Int J Pharm. 2010;390(2):89\u0026ndash;99.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eMahler H-C, Friess W, Grauschopf U, Kiese S. Protein aggregation: pathways, induction factors and analysis. J Pharm Sci. 2009;98(9):2909\u0026ndash;34.\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"},{"header":"Tables","content":"\u003cp\u003eTables 1 to 2 are available in the Supplementary Files section.\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"gene-therapy","isNatureJournal":false,"hasQc":false,"allowDirectSubmit":false,"externalIdentity":"gt","sideBox":"Learn more about [Gene Therapy](http://www.nature.com/gt/)","snPcode":"41434","submissionUrl":"https://mts-gt.nature.com/cgi-bin/main.plex","title":"Gene Therapy","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"ejp","reportingPortfolio":"Nature AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":false},"keywords":"","lastPublishedDoi":"10.21203/rs.3.rs-7596388/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-7596388/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eWhile recombinant adeno-associated virus (AAV) holds significant promise for effective and durable gene delivery for gene therapy, a thorough understanding of the critical quality attributes (CQAs) along with the degradation pathways of AAV under the various stresses that may occur during manufacturing, storage, and handling remains limited. To address this gap, we performed a comprehensive forced degradation study to elucidate the degradation pathways of AAV8 under a series of stress conditions such as oxidation, extreme pH, high temperature, freeze thaw, and agitation. Our results show that, under these stress conditions, distinct post-translational modifications (PTM), including methionine oxidation, asparagine deamidation, and aspartic acid isomerization, along with multiple physical degradation pathways, including capsid aggregation, viral protein fragmentation, and genome DNA leakage, could occur. Alterations in AAV8 biological activity were frequently attributed to the combination effect from chemical and physical degradation mechanisms. The results from this study provide a valuable insight into establishment of stability-indicating methods and identification of CQAs for AAV. It will also support the development of robust manufacturing process as well as stable and efficacious AAV gene therapy drug products.\u003c/p\u003e","manuscriptTitle":"Comprehensive Forced Degradation Study Revealing Diverse Chemical and Physical Degradation Pathways of AAV8","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-10-09 17:40:40","doi":"10.21203/rs.3.rs-7596388/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"revise","date":"2025-11-10T10:22:23+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"This content is not available.","date":"2025-10-23T20:51:17+00:00","index":2,"fulltext":"This content is not available."},{"type":"editorInvitedReview","content":"This content is not available.","date":"2025-10-14T21:51:22+00:00","index":1,"fulltext":"This content is not available."},{"type":"reviewerAgreed","content":"This content is not available.","date":"2025-10-03T13:04:40+00:00","index":2,"fulltext":"This content is not available."},{"type":"reviewerAgreed","content":"This content is not available.","date":"2025-10-01T19:10:12+00:00","index":1,"fulltext":"This content is not available."},{"type":"reviewersInvited","content":"","date":"2025-09-28T20:51:31+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2025-09-12T14:24:54+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2025-09-12T14:24:45+00:00","index":"","fulltext":""},{"type":"submitted","content":"Gene Therapy","date":"2025-09-12T04:33:53+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"gene-therapy","isNatureJournal":false,"hasQc":false,"allowDirectSubmit":false,"externalIdentity":"gt","sideBox":"Learn more about [Gene Therapy](http://www.nature.com/gt/)","snPcode":"41434","submissionUrl":"https://mts-gt.nature.com/cgi-bin/main.plex","title":"Gene Therapy","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"ejp","reportingPortfolio":"Nature AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":false}}],"origin":"","ownerIdentity":"ca694f66-68b3-4725-9548-8bc7478c760c","owner":[],"postedDate":"October 9th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[{"id":55463041,"name":"Biological sciences/Biotechnology/Gene therapy"},{"id":55463042,"name":"Biological sciences/Biological techniques/Biophysical methods"}],"tags":[],"updatedAt":"2026-02-12T08:10:54+00:00","versionOfRecord":{"articleIdentity":"rs-7596388","link":"https://doi.org/10.1038/s41434-026-00593-6","journal":{"identity":"gene-therapy","isVorOnly":false,"title":"Gene Therapy"},"publishedOn":"2026-02-12 05:00:00","publishedOnDateReadable":"February 12th, 2026"},"versionCreatedAt":"2025-10-09 17:40:40","video":"","vorDoi":"10.1038/s41434-026-00593-6","vorDoiUrl":"https://doi.org/10.1038/s41434-026-00593-6","workflowStages":[]},"version":"v1","identity":"rs-7596388","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-7596388","identity":"rs-7596388","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}